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Zusammenfassung 
Bluthochdruck (Hypertonie), also ein chronischer und dauerhafter Anstieg des Blutdrucks, ist ein 
beeinflussbarer Risikofaktor z. B. für die koronare Herzkrankheit, den hämorrhagischen Schlaganfall 
oder eine terminale Niereninsuffizienz. Trotz der wichtigen pathophysiologischen Rolle der 
Hypertonie sind die zellulären Mechanismen beim Entstehen der Erkrankung noch unklar. Während 
der Hypertonie sind die glatten Gefäßmuskelzellen (vascular smooth muscle cells, VSMCs) einer 
erhöhten Wandspannung ausgesetzt. Dies führt zu einem Wechsel des Phänotyps der VSMCs, um 
dem übermäßigen Anstieg der Wandspannung entgegenzuwirken und schließlich den Tonus des 
Gefäßes wieder herzustellen. Auf zellulärer Ebene führt eine übermäßige Dehnung zur Translokation 
des als Mechanotransducer fungierenden Proteins Zyxin von den fokalen Adhäsionen zu den 
Stressfasern und zu einem gewissen Teil auch in den Zellkern, wo es indirekt über MRTF-A 
(myocardin-related transcription factor-A) die Expression mechanosensitiver Gene reguliert. Aus 3 
Monate alten Zyxin-Knockout (Zyxko)-Mäusen isolierte VSCMs zeigten in vitro einen synthetischen 
Phänotyp. Dagegen wiesen nur sehr alte (18 Monate), mit Desoxycorticosteron-Azetat (DOCA)-Salz 
behandelte Zyxko-Mäuse einen deutlichen vaskulären Phänotyp auf, der z. B. durch einen fehlenden 
Blutdruckanstieg, einen niedrigeren Widerstandsindex, d. h. dem Widerstand in den periphären 
Blutgefäßen, und eine veränderte Zusammensetzung der extrazellulären Matrix (extracellular 
matrix, ECM) charakterisiert ist. Die Altersabhängigkeit des in vivo-Phänotyps lässt einen 
kompensatorischen Einfluss anderer Proteine mit LIM-Domäne aus der Zyxin-Familie vermuten.  
Deshalb wurde zunächst analysiert, ob LPP (lipoma preferred partner) oder TRIP6 (thyroid receptor 
interacting partner 6) beim Bluthochdruck-induzierten arteriellen Umbauprozess den Verlust von 
Zyxin kompensieren kann. Wie Zyxin transloziert auch LPP, aber nicht TRIP6 bei supra-
physiologischer Dehnung in vitro von den fokalen Adhäsionen vor allem an die Aktin-Stressfasern 
und in den Nukleus. Interessanterweise nimmt in den Arterien sehr alter Zyxko Mäuse nur LPP auf 
Proteinebene ab. Aus 3 Monate alten Lppko-Mäusen isolierte VSMCs glichen funktionell dem 
synthetischen Phänotyp von aus gleichaltrigen Zyxko-Mäusen isolierten VSMCs. Auch wenn die 
VSMCs junger (3 Monate) Lppko-Mäuse bei einer experimentell induzierten Hypertonie keinen 
synthetischen Phänotyp aufweisen, könnte der verminderte Widerstandsindex auf eine vaskuläre 
Dysfunktion bereits in diesem jungem Alter hinweisen. Die Überexpression von LPP in VSMCs aus 
Zyxko-Mäusen oder Zyxin in VSMCs aus Lppko-Mäusen konnte den Verlust der jeweiligen anderen 
Funktion vollständig kompensieren und den kontraktilen VSMC-Phänotyp wieder herstellen. Diese 
Ergebnisse charakterisieren Zyxin als neuen Regulator des Phänotyp-Wechsels bei VSMCs während 
des Bluthochdruck-induzierten arteriellen Umbaus, wobei LPP Zyxin unterstützen kann, um diesen 
Wechsel zu verhindern. 
Anders als VSCMs reagieren terminal differenzierte Kardiomyozyten (cardiomyocytes, CMs) auf 
arterielle Hypertension durch eine Vergrößerung der Zelle und normalisieren so die Wandspannung 
nach dem Gesetz von Laplace. Der auf diese kompensatorische Hypertrophie folgende Verlust von 
CMs und die übermäßige Ablagerung von ECM-Proteinen durch kardiale Fibroblasten (cadriac 
fibroblast, CFBs) führen zu einer kardialen Dysfunktion. Der Mechanotransducer Zyxin wird offenbar 
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für das Überleben der CMs benötigt. Zweites Ziel dieser Arbeit war daher zu analysieren, wie sich 
das Fehlen von Zyxin auf die kardiale Funktion bei DOCA-Salz induzierter experimenteller Hypertonie 
auswirkt. Tatsächlich zeigten 12 Monate alte Zyxko-Mäuse eine möglicherweise auf eine exzessive 
kardiale Fibrose und die daraus resultierende Versteifung des Herzens zurückzuführende kardiale 
Dysfunktion. Um diesen Befund zu bestätigen, wurde ein kardiales Fibrose-Modell etabliert, bei dem 
3, 6 und 12 Monate alte Zyxko- und Wildtyp (WT)-Mäuse über eine implantierte osmotische 
Minipumpe mit einer hohen Dosis Angiotensin II (Ang II) oder physiologischer Salzlösung behandelt 
wurden. In diesem Modell zeigten 3 Monate alte, unbehandelte Zyxko-Mäuse im Vergleich zu 
gleichaltrigen Kontrolltieren eine verminderte diastolische, aber unveränderte systolische Funktion. 
Durch die Behandlung mit Ang II verschlechterte sich die systolische kardiale Funktion fortschreitend 
mit steigendem Alter der Versuchstiere, was mit einer altersabhängigen verstärkten Kollagen-
Einlagerung im Herzen einherging. Der Einfluss von Ang II auf die interstitielle und perivaskuläre 
kardiale Fibrose war in WT-Mäusen gleichen Alters deutlich weniger ausgeprägt, was auf eine 
fortschreitende restriktive Kardiomyopathie in Zyxko-Mäusen in diesem Modell hinweist. 
Um für die ausgeprägte kardiale Fibrose in Zyxko-Mäusen verantwortliche Schlüsselmoleküle zu 
identifizieren, wurde die Expression pro-fibrotischer Gene in adulten kardialen Fibroblasten (adult 
cardiac fibroblasts, ACFs) von Zyxko- oder WT-Mäusen untersucht, die in vitro mit TGF-β1 
(transforming growth factor-β1) stimuliert wurden. Die starke Expression von CTGF (connective 
tissue growth factor), Kollagen I und III sowie der Lysyloxidase (LOX) in den ACFs der Zyxko-Mäuse 
unterstützt die Vermutung, dass die kardialen Fibroblasten zur verstärkte Ausbildung von 
Narbengewebe in den Herzen dieser Tiere beitragen. Da LOX durch die Vernetzung von Kollagen die 
Bildung unlöslicher Kollagen-Ablagerungen im Herzen verstärkt, ist es möglich, dass dies zusammen 
mit der erhöhten Synthese von Kollagen I und III maßgeblich für die Entstehung der übermäßigen 
kardialen Fibrose und somit auch für die kardiale Dysfunktion der Zyxko-Mäuse verantwortlich ist. 
Ob die Altersabhängigkeit dieses kardialen Phänotyps ähnlich wie die des vaskulären mit der 
funktionellen Kompensation zwischen Zyxin und LPP in den CFBs oder in den CMs selbst verbunden 
ist, muss noch untersucht werden. Dennoch ist es wahrscheinlich, dass ein Fehlen von Zyxin zu einer 
veränderten CM-ECM-Interaktion führt, die die Apoptose von Kardiomyocyten und in Folge oder 
parallel eine übermäßige kardiale Fibrose fördert und damit zu der beschriebenen kardialen 
Dysfunktion in adulten Zyxko-Mäusen beiträgt.  
In dieser Studie konnten die LIM-Domänen-Proteine Zyxin und LPP als redundante und protektive 
Moleküle identifiziert werden, die in VSMCs den kontraktilen Phänotyp aufrechterhalten und so 
dazu beitragen, die Entwicklung eines Hypertonie-induzierten arteriellen und möglicherweise 
kardialen Remodellings zu verhindern. Der zeitliche Unterschied beim Auftreten der durch die 
experimentelle Hypertonie induzierten Phänotypen (vaskulär und kardial) könnte auf die 
unterschiedliche Häufigkeit von Zyxin bzw. LPP in den jeweiligen Zellen der betrachteten Gewebe 
zurückzuführen sein. Daher könnten Untersuchungen von alten Lppko und Lpp/Zyx Doppelknockout-
Mäusen weiteren Aufschluss über ihre mögliche funktionelle Kompensation im Rahmen eines 
Hypertonie-induzierten Umbauprozesses geben. 
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Summary 
Hypertension, a chronic and persistent increase in blood pressure, is a modifiable risk factor for, e.g. 
coronary heart disease, hemorrhagic stroke and end-stage renal failure. Despite the 
pathophysiological importance of hypertension, understanding of the cellular mechanisms at the 
onset of this disease remains elusive. During hypertension, vascular smooth muscle cells (VSMCs) 
are exposed to increased wall stress. This promotes a phenotype shift of the VSMCs to overcome the 
undue rise in wall stress and eventually reinstate vascular tone. At the cellular level, excessive 
stretch induces translocation of the mechanotransducer protein zyxin from focal adhesions to stress 
fibers and to some extent to the nucleus where it indirectly via myocardin-related transcription 
factor-A (MRTF-A) fine-tunes the expression of mechanosensitive genes. VSMCs isolated from 3-
months old zyxin knockout (Zyxko) mice showed a synthetic phenotype. In contrast, only 
deoxycorticosterone acetate (DOCA)-salt treated very old (18-months) Zyxko mice revealed a 
prominent vascular phenotype exemplified by failure to develop hypertension, a lower resistivity 
index, i.e. peripheral resistance, and an altered composition of the extracellular matrix (ECM). The 
age dependency of the in vivo phenotype argues for a possible compensation by other LIM-domain 
proteins of the zyxin family.  
Therefore, the first aim was to analyze whether LPP (lipoma preferred partner) or TRIP6 (thyroid 
receptor interacting partner 6) might compensate for the loss of zyxin in hypertension-induced 
arterial remodeling. Like zyxin, LPP but not TRIP6 in vitro translocated from focal adhesions 
predominantly to actin stress fibers as well as to the nucleus upon exposure to supraphysiological 
stretch. Interestingly, only the level of LPP protein significantly declined in arteries of very old Zyxko 
mice. VSMCs isolated from 3-months old Lppko mice functionally mimicked the synthetic phenotype 
of VSMCs isolated from age-matched Zyxko mice. Although young Lppko mice (3 months old) failed 
to reveal a synthetic VSMC phenotype in experimental hypertension, their significantly lower 
resistivity index may point to the presence of some vascular dysfunction at this young age. 
Overexpression of either Lpp in Zyxko VSMCs or Zyx in Lppko VSMCs fully compensated for their 
alternate loss of function in restoring the contractile VSMC phenotype. Hence, these findings 
characterize zyxin as a novel regulator of the phenotypic shift of VSMCs during hypertension-
induced arterial remodeling with LPP capable of reinforcing zyxin in preventing this shift to occur.  
Distinct from VSMCs, terminally differentiated cardiomyocytes (CMs) respond to arterial 
hypertension by increasing their cell size hence thickness of the ventricular wall (hypertrophy) 
thereby normalizing wall stress according to the law of Laplace. Following this compensatory CMs 
hypertrophy, loss of CMs as well as excessive deposition of ECM proteins by cardiac fibroblasts 
(CFBs) causes cardiac dysfunction. The mechanotransducer zyxin seems to be important for CMs 
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survival. Therefore, the second aim of this work was to study the consequences of the loss of zyxin 
for cardiac function in DOCA-salt induced experimental hypertension. In fact, 12 months old Zyxko 
mice showed cardiac dysfunction possibly due to excessive cardiac fibrosis and the resulting 
stiffening of the heart. To corroborate this finding, a cardiac fibrosis model, where 3, 6 and 12 
months old Zyxko and wild type (WT) mice are treated with a high dose of angiotensin II (Ang II) or 
saline delivered through implanted osmotic mini pumps, was established. In this model, untreated 3 
months old Zyxko mice presented with a reduced diastolic but preserved systolic function as 
compared to age-matched WT mice. Upon Ang II treatment, systolic cardiac function progressively 
deteriorated in the Zyxko mice with age and this was paralleled by a prominent age-dependent rise 
in collagen deposition in the heart. The effects of Ang II on both interstitial and perivascular cardiac 
fibrosis were significantly less pronounced in age-matched WT mice, indicative of the development 
of a progressive restrictive cardiomyopathy in the Zyxko mice in this model. 
To identify key molecule(s) responsible for the profuse cardiac fibrosis in Zyxko mice, pro-fibrotic 
gene expression profiles were studied in adult cardiac fibroblasts (ACFs) isolated from Zyxko or WT 
mice that were exposed in vitro to transforming growth factor-β1. Prominent expression of 
connective tissue growth factor, collagens I and III as well as lysyl oxidase (LOX) by the Zyxko ACFs 
supports the notion that CFBs account for the excessive formation of scar tissue in the heart of these 
animals. Since LOX augments the formation of insoluble collagen deposits in the heart, namely by 
cross-linking them, it might be together with the enhanced synthesis of collagens I and III primarily 
responsible for the exaggerated cardiac fibrosis and hence cardiac dysfunction in the Zyxko mice. 
Whether the age-dependency of this cardiac phenotype is like the vascular phenotype related to a 
functional compensation between zyxin and LPP in the CFBs or even CMs remains to be determined. 
Nonetheless, it is likely that the lack of zyxin leads to an altered CM-ECM interaction facilitating CM 
apoptosis and in turn or in parallel excessive cardiac fibrosis hence contributing to the observed 
cardiac dysfunction in adult Zxyko mice. 
In summary, the findings of this study characterize the LIM-domain proteins zyxin and LPP as 
redundant protective molecules that help to maintain the contractile VSMC phenotype and thus 
contribute to impeding the development of hypertension-induced arterial and possibly cardiac 
remodeling. The temporal difference in the appearance of two distinct hypertension-induced 
phenotypes (vascular and cardiac) might be attributed to the differential abundance of zyxin and LPP 
in the respective tissue-resident cells contributing to the pathogenesis. Therefore, analysis of old 
Lppko as well as Lpp/Zyx double-knockout mice has the potential to shed more light on their 
possible functional compensation in the context of hypertension-induced cardiovascular remodeling 
processes. 
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1 Introduction 
1.1 Hypertension: A silent killer 
Blood is pumped, with each heartbeat to all parts of the body through the arterial blood vessels. 
Thus, blood pressure is established by the force of blood pushing against the walls of these blood 
vessels. The peak pressure that is developing during the beating of the heart, i.e. when the volume 
of blood ejected from the left ventricle travels down the arterial system, is called systolic blood 
pressure whereas the resting pressure that is observed between the heart beats is called diastolic 
blood pressure. Mean arterial pressure is regulated by cardiac output and the total peripheral 
resistance in the vessel1. According to the world health organization (WHO) hypertension is a 
pathophysiological condition in which the blood vessels experience persistently elevated pressure. 
Persistent elevation of systolic blood pressure greater than 140 mmHg and diastolic blood pressure 
greater than 90 mmHg are considered as clinical hypertension2. On its own, arterial hypertension is 
asymptomatic and in about 5% of cases, a specific (organ-related) cause can be found for the 
elevated blood pressure, known as secondary hypertension. However, for the remaining 95% of 
cases no etiology can be defined, hence this condition is referred to as primary hypertension. 
Chronic hypertension is a chief risk factor for the development of ischemic heart disease and stroke, 
which remained the number 1 and 2 leading causes of death globally in the last 15 years3. 
1.2 Induction of cardiovascular remodeling during hypertension 
Hypertension induces the transmural pressure difference that elicits circumferential wall stress 
according to the law of Laplace4. This increased wall stress can induce maladaptive, i.e. 
pathophysiological remodeling processes in the heart, arterial or even venous blood vessel wall by 
an interplay of tissue-resident cells such as endothelial cells (EC), vascular smooth muscle cells 
(VSMC), cardiomyocytes (CMs) or cardiac fibroblasts (CFBs) with some contribution by infiltrating 
leukocytes.  
1.2.1 Remodeling of the blood vessel wall: VSMCs in focus 
Typically, an artery consists of three structural layers, namely intima, media and adventitia. 
Endothelial cells are longitudinally arranged in the intima and VSMCs are circumferentially arranged 
in the media together with connective tissue. Both layers get separated by an internal elastic lamina. 
The adventitia contains many components, including, in most cases, sympathetic nerves, 
considerable amounts of collagen, and fibroblasts2. VSMCs are dynamic, multifunctional cells that 
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contribute to arterial remodeling through numerous processes, including cell growth (hyperplasia 
and/or hypertrophy), apoptosis, elongation of cells, reorganization of cells, and/or altering 
composition of the  extracellular matrix (ECM)5. The primary functional property of an arterial blood 
vessel is to maintain a certain lumen diameter, which determines vascular resistance (according to 
the Poiseuille’s law) and hence blood flow to the downstream organs or organ substructures. 
Arterial hypertension typically causes a chronic rise in wall stress imposing an enhanced cyclic strain 
on the VSMCs, which triggers a shift in their phenotype switching from a quiescent, contractile state 
to a proliferative and synthetic state. This phenotype switching finally establishes VSMC hypertrophy 
or hyperplasia in the vascular wall, depending on the size of the arterial blood vessel, thereby 
increasing wall thickness to counter-balance the rise in wall stress (Figure 1.1 A,B)6–8. The 
differentiated and contractile VSMCs express a broad repertoire of genes such as smooth muscle α-
actin (SMA), smooth muscle myosin heavy chain (SM-MHC), smooth muscle myosin light chain (SM-
MLC), calponin, smooth muscle α-tropomyosin, smoothelin, desmin and vinculin (Figure 1.1 C)5,9,10.  
 
 
Figure 1.1 Hypertension induced arterial remodeling 
(A) Inward eutrophic remodeling of small arteries can be triggered by low blood flow, chronic vasoconstriction, 
and hypertension. (B) Schematic representation of a cross section of the arterial vessel wall in normotension and 
hypertension, respectively. Arterial remodeling is characterized by thickening of the wall where switching of the 
VSMC phenotype (dedifferentiation) and remodeling of the ECM take place. (C) Schematic representation of 
expression levels of genes associated with a particular SMC phenotype (adapted from10–12). Abbreviations: ECM, 
extracellular matrix; SMA, smooth muscle α-actin; ACLP, aortic carboxypeptidase-like protein; APEG-1, aortic 
preferentially expressed protein-1; CRP-2, c-reactive protein-2; SM-MHC, smooth muscle myosin heavy chain; 
CRBP-2, retinol-binding protein-2; PDGF, platelet derived growth factor; ICAM-1, intercellular adhesion 
molecule-1; MGP, matrix gla protein-1; MMP, matrix metalloproteinase. 
Introduction  3 
 
The phenotype shift of VSMCs in small resistance-sized arteries is characterized by a marked 
reduction in expression of VSMC-selective differentiation marker genes (Figure 1.1 C)9,10 together 
with increased proliferation, migration, and synthesis of extracellular matrix components. 
1.2.2 Remodeling of the heart: cardiac fibroblasts in focus    
Increased biomechanical stress during hypertension (pressure overload) induces hypertrophy of the 
cardiomyocytes which in turn increases thickness of the wall of the left ventricle to neutralize the 
increased wall stress13. Terminally differentiated cardiomyocytes (CMs) respond to pressure-
overload stress by enlarging their size rather than proliferation because of their incapability to 
reenter the cell cycle. This pro-hypertrophic response is accompanied by enhanced protein synthesis 
as well as higher organization of the sarcomeric structure. As part of this process, a wide range of 
transcriptional and posttranslational events occur, including re-expression of fetal genes, the so-
called pro-hypertrophic gene program.  
At the early stage of hypertension this pro-hypertrophic response of the CMs is considered adaptive, 
ultimately to diminish wall stress and to decrease oxygen demand. However, in fact this remodeling 
process is maladaptive because it impairs adequate fractional shortening of the CMs and in parallel 
hampers diffusion of oxygen from the nearby capillaries, thus causing early systolic dysfunction of 
the left ventricle. Moreover, when pressure overload due to arterial hypertension persists, cardiac 
remodeling eventually is sped up, resulting in a more severe dysfunction ultimately leading to heart 
failure14. CMs apoptosis is much enhanced while the proliferating cardiac fibroblasts differentiated 
to myofibroblasts secrete large amounts of ECM proteins to replace the dead myocardium by scar 
tissue. This surplus of ECM protein deposition around the blood vessels (perivascular) and 
throughout the interstitium causes a stiffening of the heart that enhances CMs apoptosis and the 
subsequent fibrosis even further and ultimately results in a condition that is referred to as 
hypertrophic or restrictive cardiomyopathy and will inevitably lead to heart failure (Figure 1.2). 
Moreover, cardiac fibrosis disrupts the coordination of myocardial excitation-contraction coupling in 
both systole and diastole to promote arrhythmia15–17. 
Fibroblasts (FBs), morphologically flat and spindle shaped cells with multiple projections, comprise 
the largest cell population in the myocardium. A variety of cell surface markers has been identified 
for both FBs and cardiac fibroblasts (CFBs), i.e. vimentin, discoidin domain receptor 2 (DDR-2) or 
fibroblast-specific protein 1 (FSP-1), although their specificity for these cells has been repeatedly 
challenged18. In chronic hypertension, CFBs can differentiate into myofibroblasts, which are more 
mobile and contractile with a greater synthetic ability to produce ECM proteins (Figure 1.2). 
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Myofibroblasts are present in the myocardium only following cardiac injury as the healthy 
myocardium is devoid of them17,19. These cells are defined according to their dual functions: 
fibroblast-like in terms of ECM synthesis and smooth muscle myocyte-like in terms of migration. 
Although, similar to CFBs, myofibroblasts are also non-excitable cells but express a number of 
smooth muscle cell markers such as SMA, SM-MHC, vinculin and paxillin15,20,21.  
 
 
Figure 1.2 Transdifferentiation of fibroblasts to myofibroblasts during hypertension 
A supraphysiological rise in wall stress triggers the differentiation of fibroblasts into proto-myofibroblasts and 
finally to myofibroblasts. Myofibroblasts are characterized by their expression of α-smooth muscle actin and 
well developed stress fibers; they primarily contribute to scar tissue formation (adpated from17). 
In the setting of pathological stress, the source of this highly active fibroblast might include resident 
fibroblasts, adult epicardial cells undergoing endothelial-to-mesenchymal transition, and circulating 
collagen-secreting bone marrow-derived cells22. Myofibroblast-mediated collagen turnover is 
regulated by autocrine and paracrine factors generated within the myocardium and by endocrine 
hormones derived from the circulation. Transforming growth factor-β1 (TGF-β1) induces this 
process to reinforce collagen expression, whereas IL-1β prevents differentiation of CFBs to 
myofibroblasts23,24. In the myocardium, this transdifferentiation induces ECM turnover in favor of 
increased synthesis and accumulation of ECM proteins to replace lost myocytes and/or interrupt 
myocyte–myocyte interactions, resulting in an overall deterioration of cardiac function (Figure 
1.2)20.  
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1.2.3 Remodeling of the extracellular matrix: in the arterial vessel wall and in the 
myocardium 
The arterial vessel wall is an active, flexible, and integrated dynamic organ made up of cellular (ECs, 
VSMCs, and FBs) and non-cellular (ECM) components, which undergo reorganization in response to 
pathophysiological stimuli. This structurally determined change in lumen diameter is designated 
vascular remodeling and medial VSMCs play a pivotal role therein5,25. In the media, these cells are 
surrounded by and embedded into different ECM proteins including collagen, elastin and 
proteoglycans that are organized into a highly ordered network. During remodeling, activated 
VSMCs degrade and breach the surrounding ECM to support their migration and release of growth 
factors. Quantitative, topographic or both changes in ECM composition  alter medial VSMC-ECM 
interaction, resulting in a rearrangement of both VSMCs and ECM proteins, and hence a 
restructured arterial vessel wall26,27. In arterial hypertension, induction of collagen and elastin 
synthesis by VSMCs combined with a reduced degradation of these matrix proteins results in 
stiffening of the arterial vessel wall28. Additionally, the receptors for these ECM proteins such as 
integrins also contribute to the remodeling process by perceiving and subsequent transduction of 
the signals into the recipient tissue-resident cells29. Moreover, tissue transglutaminase-2 (tTG-2) 
could be involved in the remodeling process by mediating interactions between integrins and ECM 
proteins30,31. Matrix metalloproteinases (MMPs), a family of zinc and calcium dependent 
endopeptidases, are able to degrade collagen, elastin, and other extracellular molecules. The activity 
of MMPs is regulated by conversion of the inactive pro-form to the active form as well as inhibition 
by specific tissue inhibitors of MMPs (TIMPs). While MMP1 and 13 are collagenases, MMP2 and 9 
are gelatinases; in contrast MMP3 rather has a broad spectrum of activity32. MMP2 and MMP9 play 
a pivotal role in vascular remodeling by controlling VSMC migration12,33.  
In hypertensive heart disease, altering the composition and degree of crosslinking of the ECM is a 
key component of cardiac remodeling, where disintegration of the ECM affects the structural 
integrity as well as function of the left ventricle34. In contrast, excessive production, accumulation 
and crosslinking of ECM proteins, e.g. cardiac fibrosis, results in stiffening of the myocardium 
distorting left ventricular architecture and function35. Myocardial stiffness is largely attributed to 
changes in type I and III fibrillar collagens secreted from the myofibroblasts as pro-collagens and 
eventually assembled into the mature collagen fibers. A number of growth factors/mitogens such as 
angiotensin II (Ang II), TGF-β1, insulin like growth factor-1 (IGF-1), and tumor necrosis factor-α (TNF-
α) may act synergistically to regulate collagen turnover by the  myofibroblasts20,36. It has been 
shown that lysyl oxidase (LOX)-dependent collagen crosslinking is a prerequisite for the 
development of cardiac fibrosis and systolic dysfunction in different pathological situations37,38. 
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Moreover, an imbalance in the ratio of MMPs to their inhibitors, TIMPs, has significance for the 
progression of systolic dysfunction, hence stresses the importance of studying both ECM 
degradation mechanisms and those that underlie ECM synthesis39. Counterintuitively, degradation 
of collagen was shown to accelerate synthesis of the ECM itself40,41. Hence, MMP activation 
reinforces cardiac fibrosis by taking part in a vicious circle in which ECM degradation promotes ECM 
protein synthesis and thus scar tissue formation20.  
1.3 Mechanotransduction: focal adhesions (FA) in focus 
Intramural cells sense their local chemomechanical environment and remodel the ECM to provide 
suitable compliance and sufficient strength42,43. The dynamic process by which cells convert a 
mechanical stimulus into biochemical events is known as mechanotransduction. At the cellular level, 
mechanical forces are crucial in regulating cytoskeletal organization, gene expression, proliferation 
and survival44,45. Effects of physical forces on cellular activity are most apparent in blood pressure 
regulation, the endothelial cells response to fluid shear stress and remodeling of bone44,45. 
Intracellular actin bundles are mechanically linked to integrins on the cell surface and the ECM 
through multi-protein structures known as focal adhesions (FAs)46. FAs serve as molecular bridges 
that coordinate a variety of environmental stimuli and facilitate communication between the ECM 
and the cytoskeleton47. Formation of these structures requires tension generated by cellular 
actomyosin networks, resisted by a substratum of sufficient stiffness (Figure 1.3 A). Hence, the 
assembly rate, size and functional impact of FAs depend on the contractile capacity of the 
cytoskeleton, composition of the ECM, integrin activation and avidity, and further specifics of the 
microenvironment48,49. Within FAs, mechanotransduction could be propagated either via increased 
integrin clustering or alterations in the conformation of certain force-sensitive components like 
zyxin, paxillin, talin, vinculin and Ena/VASP (Figure 1.3 B)50,51. 
1.4 Zyxin as a mechanotransducer 
Zyxin, a 82 KDa LIM domain containing protein found in FAs, regulates actin polymerization51–53. It 
has been shown that a reduction in cellular traction force leads to disassembly of FAs by inducing 
the molecular unbinding kinetics of zyxin but not that of its binding partner vinculin54. Cyclic stretch, 
an in vitro model resembling one important aspect of arterial hypertension, induces the 
phosphorylation mediated translocation of zyxin into nucleus (Figure 1.4)55. Herein, zyxin can 
interact with DNA and act as a transcription factor to regulate the expression of mechanosensitive 
genes (Figure 1.4)56,57. Another possibility is that zyxin may stabilize actin dynamics and thus prevent 
transcriptional co-activators such as myocardin-related transcription factor-A (MRTF-A) from 
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entering the nucleus and interacting with serum response factor (SRF) to alter mechanosensitive 
gene expression, e.g. in VSMCs exposed to cyclic stretch58. 
 
 
Figure 1.3 Structural and molecular organization of focal adhesions 
(A) Focal adhesions are multi-layer arrangements of different proteins connecting the ECM with the cortical 
actin cytoskeleton. Formation of focal adhesions is dependent on the tension generated by cortical actin 
cytoskeleton and the traction force generated by the ECM. (B) Integrins establish attachment of the cortical 
actin cytoskeleton to the ECM at the matrix receptor binding site of focal adhesions. The intracellular domain 
contains 3 functional layers: (i) the intracellular signaling layer consisting of focal adhesion kinase and 
intracellular integrin domains, (ii) the force transduction layer consisting of proteins like zyxin, paxillin, talin, 
vinculin and Ena/VASP, and (iii) the actin regulatory layer essentially composed of actin filaments and myosin 
(adapted from50). 
 
Figure 1.4 Mechanism for the stretch-induced phosphorylation and translocation of zyxin from 
focal adhesions to nucleus in endothelial cells 
Cyclic stretch causes a diacylglycerol/TRPC3 mediated rise in intracellular calcium that triggers the release of 
ANP which in turn stimulates particulate guanylyl cyclase and subsequently protein kinase G (PKG). PKG 
phosphorylates zyxin at serine-142 thus enabling its translocation to the nucleus where it acts (in this particular 
case) as a transcription factor (adapted from55). 
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1.5 The zyxin family of LIM-domain containing proteins 
The LIM-domain consists of approximately 55 amino acids with 8 highly conserved residues and, is 
present in a wide variety of eukaryotic proteins but absent in prokaryotes. The LIM-domain was 
identified as a common cysteine-rich sequence in a small group of homeodomain transcriptions 
factors, Lin11, Isl-1, Mec-3 (LIM), and named after their origin59. The LIM-domain is devoid of 
intrinsic catalytic activity, however, it can function as adaptor, competitor, auto inhibitor or localizer 
for other protein. LIM-domain containing proteins together with partner proteins can regulate 
various biological processes including actin cytoskeletal dynamics, integrin-dependent adhesion and 
signaling, cell-fate determination, neuronal guidance as well as tissue-specific gene expression59,60. 
According to sequence similarity, LIM-domain containing proteins can be classified into four broad 
categories (Figure 1.5). The zyxin family belongs to the ‘LIM actin associated’ category and consists 
of 7 members: ajuba, LIM domain-containing protein 1 (LIMD1), LIM-domain containing preferred 
translocation partner in lipoma (LPP), migfilin, thyroid receptor interacting partner 6 (TRIP6), wilms 
tumor protein 1-interacting protein (WTIP) and zyxin. All proteins in this family have an N-terminal 
proline-rich region (PRR), three highly conserved LIM-domains at their C-terminus and other non-
LIM domains which take part in association with other proteins59. 
1.5.1 Ajuba 
Ajuba harbors a functional nuclear export signal (NES) at the pre-LIM region which facilitates the 
shuttling of this protein from cell-cell contacts to the nucleus to modulate cell growth and 
differentiation61. Ajuba can promote meiotic maturation of Xenopus oocytes through the induction 
of MAPK activity62. Ajuba knockout mice lack any obvious phenotype. Nevertheless, primary 
embryonic fibroblasts (EFs) isolated from this mice exhibited reduced migration63. Recently, ajuba 
has been shown to be involved in metastasis of esophageal squamous cell carcinoma by 
upregulating MMP10 and MMP1364. In addition, ajuba can either limit Hippo regulation via YAP-
LATS or represses the expression of tumor suppressor genes via JAK1/STAT1 to support cell 
proliferation65,66. 
1.5.2 LIMD1 
LIMD1 contains a leucine-rich NES within its pre-LIM region which accounts for its nuclear 
localization. LIMD1 is involved in cell anchoring via focal adhesions and some breast tumors reveal 
an altered LIMD1 expression67,68. LIMD1 can serve as tumor suppressor by interacting with the 
retinoblastoma protein (pRB)69.  
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Figure 1.5 Classification and domain structures of LIM domain containing proteins  
(A) LIM domain families are classified into four groups according to sequence similarity and homology within the 
LIM sequence. The domain structures of the founding member and/or the best characterized example are 
shown for each family of LIM domain containing proteins. The number of known members of each family is 
indicated in parentheses. Individual LIM domains are shown as colored ovals. Dashed lines indicated that scale is 
not preserved. (B) A list of the identified members of each LIM domain containing protein family. Abbreviations: 
CH, calponin homology; GLY, glycine-rich region; PDZ, postsynaptic density-95, Discs large, zona occludens-1; 
PET, prickle, espinas and testin; SH3, Src-homology-3; VHP, villin head piece. (Adapted from59). 
1.5.3 WTIP 
WTIP (WT1-interacting protein) was identified as a binding partner of WT1 (Wilms’ tumor gene 
protein 1), a zinc finger transcription factor, and can regulate glomerular podocyte differentiation by 
shuttling between focal adhesions and the nucleus. It contains three C-terminal LIM domains and a 
pre-LIM prolin-rich region in which the NES is located. In normal glomeruli, WTIP is part of a 
multiprotein complex in podocyte foot processes. After injury, WTIP translocates to the nucleus 
where it co-localizes with WT1 and represses WT1-dependent gene expression70. Moreover, 
together with ajuba and LIMD1, WTIP has been proposed to be involved in microRNA mediated 
gene silencing through the miRISC complex71. 
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1.5.4 Migfilin 
Migfilin contains an N-terminal region with binding sites for filamin, a central prolin-rich region in 
which a vasodilator-stimulated phosphoprotein (VASP) binding site has been identified, and a C-
terminal LIM region which mediates the interaction with other proteins. Migfilin can also travel from 
the cytoplasm to the nucleus in a calcium dependent manner72. By interacting with different partner 
proteins this adapter protein can modulate cell shape and motility73,74 as well as cardiac 
development75. In response to pressure overload, migfilin knockout mice hearts showed less 
hypertrophy and fibrosis76. Downregulation of migfilin was observed in VASP depleted breast cancer 
cells which in turn inhibited tumor spheroid invasion77.   
1.5.5 TRIP6/ZRP-1 
Thyroid hormone receptor interacting protein 6 (TRIP6), also known as zyxin-related protein-1 (ZRP-
1), contains a NES, multiple transactivation domains (one overlaps with sequences of the NES) and a 
nuclear targeting sequence both in the PRR and in the LIM-domains78. Three different isoforms of 
TRIP6 have been described and the shortest form has been termed nuclear isoform of TRIP6 
(nTRIP6)79. According to its localization both in focal adhesions and in the nuclear compartment, 
TRIP6 has also been proposed as a molecule that transmits signals between adhesion sites and the 
nucleus78,80. TRIP6 was demonstrated to be essential for stress fiber formation through reorganizing 
of the cortical actin cytoskeleton via modulation of Rho GTPase81. Moreover, TRIP6 interacts with 
p130Cas family member of signal transduction through SH2 domain to regulate cellular motility82,83. 
Depending on the interacting transcription factor, TRIP6 can function either as a transcriptional co-
activator or co-repressor. During cancer-associated inflammatory response and tumorigenesis, 
TRIP6 can associate with the lysophosphatidic acid-2 (LPA-2) receptor, and serve as a co-activator 
for several transcription factor like nuclear factor-κB (NF-κB) as well as c-Jun N-terminal kinases 
(JNK), i.e. the activator protein-1 (AP-1) pathway84. In addition, nTRIP6 can serve as a co-activator for 
NF-κB, AP-1 or myocyte enhancer factor-2 C (MEF2C) to regulate different cellular responses79,85. It 
was found to be a selective co-activator for AP-1 dimers containing Fos86, and has been associated 
with proteins ensuring telomere protection87. 
1.5.6 LPP 
The Lpp (lipoma preferred partner) gene was identified first as the most frequent translocation 
partner of the HMGA2 (high mobility group A2) gene in lipomas and later in a number of other soft 
tissue tumors88,89. However, in acute monoblastic leukaemia, the Lpp gene was shown to act as a 
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translocation partner of the MLL (mixed lineage leukaemia) gene90. Like TRIP6, the LPP protein 
contain a NES located at the leucine-rich pre-LIM region and can shuttle from focal adhesions to the 
nucleus where it displays transcriptional activation capacity91. It has been demonstrated that within 
the nucleus LPP acted as a coregulatory protein to enhance the transactivation potential of PEA3, a 
regulatory region associated with tumorigenesis as well as embryogenesis92. The localization of LPP 
to FAs is largely mediated by the LIM-domains rather than the pre-LIM region which harbors the α-
actinin and VASP binding sites93. LPP has occasionally been observed along stress fibers94 and a 
specific region within the pre-LIM region is required for their this actin stress fibers targeting95.  
In 2003, two independent studies reported LPP as a novel smooth muscle cell (SMC) marker96,97. 
Later, it was found that LPP was also involved in the regulation of vascular SMC migration in an in 
vitro model for vascular injury98. In SMCs, LPP expression can be mediated by an alternative 
promoter that is regulated by serum response factor/myocardin99. It has been suggested that LPP 
expression could be regulated by non-canonical Wnt signaling and might be involved in Rho kinase 
2-dependent signaling pathways in human iliac vein SMCs98. In zebrafish, LPP has been shown to 
interact with the Wnt/PCP protein Scrib to regulate cell migration and intercalation during 
convergence and extension movement in early embryonic development100. Moreover, LPP can 
positively regulate invadopodia formation to enhance breast cancer metastasis by binding to the Src 
substrate ErbB2101,102.  Surprisingly, Lpp knockout (Lppko) mice do not exhibit any defect during 
embryonic development and are viable103. They reach adulthood without displaying any obvious 
macroscopic or microscopic abnormalities possibly due to functional redundancy among the closely 
related members belonging to the zyxin family of LIM protein (Figure 1.6)103. However, an aberrant 
Mendelian inheritance was observed in heterozygous mating which could be explained by the 
partial embryonic lethality in knockout females103. 
 
Figure 1.6 Evolutionary relationship and similarity in the domain structure among the zyxin family 
of LIM domain-containing proteins  
(A) Cladogram of a phylogenetic tree for members of the zyxin family. Full-length protein sequences were 
obtained from Entrez Protein Database (National Center for Biotechnology Information (NCBI), and their 
sequences were aligned and phylogenetic tree was constructed using the web tool CLUSTAL Omega. The 
phylogenetic tree was visualized with TreeView (version 1.6.6, 2001). Scale bar represents 0.1 amino acid 
substitution per site. (B) Scheme of the subdomain structure of the most closely related zyxin family member i.e. 
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zyxin, LPP and TRIP6. All proteins contain a C-terminal cysteine-rich portion composed of 3 LIM domains and an 
N-terminal proline-rich domain. Both LPP and zyxin also harbor an α-actinin binding motif and 2 or 4 Act A 
repeats which facilitate the binding of Ena/VASP family proteins. In contrast, TRIP6 is relatively shorter and 
devoid of the binding site for α-actinin and VASP (adapted from91). 
1.5.7 Zyxin 
Zyxin, the founding member of the family, is a phosphoprotein that localizes at focal adhesions and 
along actin filaments104. Zyxin contains four proline-rich repeats that serve as binding sites for Mena 
(mammalian Ena) and VASP in the pre-LIM region and three zinc finger containing LIM domains (for 
interaction with the DNA) at the C-terminus. Depending on the species, zyxin contains one or more 
leucine-rich nuclear export signals105. Several lines of evidences suggest that zyxin plays an 
important role in localizing members of the Mena/VASP family to sites of cell adhesion106. Zyxin has 
been shown to be involved in the assembly of the actin cytoskeleton as well as in the maintenance 
and repair of actin stress fibers to retain mechanical homeostasis107. Moreover, zyxin can regulate 
endothelial cell exocytosis through reorganizing the local actin network as, e.g. during the release of 
von Willebrand factor (VWF) from Weibel–Palade bodies (WPB)108. Moreover, it has been shown 
that exposure to cyclic stretch causes dissociation of zyxin from focal adhesions both in ECs and  
VSMCs to either associate with actin stress fibers or to accumulate in the nucleus where it can act as 
a transcription factor55–57,109. Thus, zyxin can regulate the expression of a vast majority (90%) of 
mechanosensitive genes, e.g. in VSMCs, hence strongly affecting their cell cycle regulation, 
mitogenesis and contractile capacity58. In fact, VSMCs isolated from zyxin knockout (Zyxko) mice 
revealed a shift from the contractile to the synthetic phenotype which could be attributed to an 
increased RhoA activity and persistence of myocardin related transcription factor-A (MRTF-A) in the 
nucleus58.  
Although zyxin is ubiquitously expressed in mice both during embryonic development and in 
adulthood, mice that lack zyxin are viable, fertile and do not show any discernible abnormalities110. 
It was therefore suggested that the absence of a phenotype in Zyxko mice might be accredited to a 
possible functional overlap between zyxin and a closely related member of the zyxin family of LIM 
domain-containing proteins (Figure 1.6)110. Reinforcing this assumption adult Zyxko mice only 
revealed the same synthetic phenotype as VSMCs isolated from 3-months old Zyxko mice when 
subjected to experimental arterial hypertension. While a cardiac phenotype (systolic dysfunction) 
was unmasked at 12 months of age, the vascular phenotype (poor myogenic response) only became 
apparent at 18 months of age111 . This age-dependency argued for a possible functional redundancy 
mediated by other members of the zyxin family of LIM-domain-containing proteins, namely LPP and 
TRIP6.  
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1.6 Aims of the thesis 
By considering the aforementioned findings in assigning a role for zyxin in experimental 
hypertension, two main aims were devised for this doctoral thesis. 
1. The first focus was to analyze the presumed functional redundancy among the most closely 
related members of zyxin family of LIM-domain-containing proteins, i.e. LPP and TRIP6, in 
hypertension-induced arterial remodeling.  
i. In the first part of the study, expression levels of these two potential compensators were 
analyzed in selected arterial blood vessels derived from Zyxko mice of different age. 
Moreover, their responses to cyclic stretch were analyzed and compared to that of zyxin. 
ii. Next, analysis of the phenotype of mice lacking LPP or TRIP6 was considered. However, so 
far a mouse lacking TRIP6 is not available and the data obtained for TRIP6 in stretched 
VSMCs did not reveal a major role for this protein as a potential mechanotransducer. Lppko 
mice, on the other hand, proved viable but similar to Zyxko mice revealed no phenotype at 
baseline. Therefore, the role of LPP in VSMC function was analyzed in vitro by focusing on 
three major aspects of the contractile VSMC phenotype, i.e. migration, proliferation and 
contractile capacity. In addition, Lppko mice were subjected to deoxycorticosterone acetate 
(DOCA)-salt induced experimental hypertension, and both their vascular and cardiac 
phenotype studied by a combination of telemetry-based blood pressure recording and high 
resolution ultrasound imaging of the heart and the conduit arteries. 
iii. Finally, the potential of zyxin and LPP to compensate for their alternate loss of function was 
analyzed in vitro by overexpression of zyxin in Lppko VSMCs and vice versa of LPP in Zyxko 
VSMCs.  
2. Secondly, the previously observed cardiac phenotype of Zyxko mice in DOCA-salt induced 
experimental hypertension should be corroborated in a second model of experimental 
hypertension where cardiac fibrosis dominates despite a comparable pressure overload. 
i. To achieve this goal, 3, 6 and 12-months old Zyxko mice as well as age-matched wild type 
(WT) mice were subjected to a high dose treatment with angiotensin II, delivered by osmotic 
mini-pumps implanted in these animals, followed by characterization of their cardiac 
phenotype essentially as described before.   
ii. Finally, in search for key mediators and cells responsible for developing the prominent 
cardiac fibrosis in Zyxko as compared to WT mice, adult cardiac fibroblasts were isolated 
from the hearts of these animals and analyzed in vitro for their capacity to express pro-
fibrotic gene products at baseline and following exposure to transforming growth factor-β1 
(TGF-β1). 





Bacterial culture tubes Sarstedt 
BioFlex® Culture plate (collagen type-1 coated) Flexcell International Corporation  
Cell culture dishes TPP 
Cell culture flasks (T25, T75) Sarstedt 
Cell culture plates Sarstedt, Greiner 
Cell scraper Sarstedt 
Cover slips for microscopy Thermo Scientific 
Filter papers Munktell 
Microscope slides Thermo Scientific 
PCR tubes Sarstedt 
Pipette tips Sarstedt 
Plastic pipettes Sarstedt 
PVDF transfer membranes Immobilon®-P (Merck Millipore) 
Safe lock tubes Sarstedt 
Sterile filters GE Healthcare 
U-bottom 96 well plate Greiner 
2.2 Equipment’s 
Equipment Supplier (Model) 
Autoclave Tuttnauer (5050 EL) 
Bacterial incubator New Brunswick Scientific (Innova 4230) 
Balance Sartorius (BP121S) 
Centrifuge Hettich Zentrifugen (Universal 32) 
CODA-tail cuff Kent Scientific Corporation 
 
CO2  incubator 
New Brunswick Scientific (Innova CO-170) 
Heraeus Instruments (BB-16) 
Thermofisher Scientific (HeracellTM VIOS 160c) 
Cooling plate Leica (EG1140C) 
Cooling centrifuge HERMLE (Z323K) 
Confocal microscope Olympus (IX81) 
Flexercell system Flexcell® International (FX-5000) 
GentleMACS C Tubes Miltenyi Biotec (130-093-237) 
GentleMACS dissociator Miltenyi Biotec (130-093-235) 
High resolution ultrasound VisualSonics (Vevo2100) 
Heating block HLC-Haep Labor Consult (HBT-1131) 
Heating chamber Memmert (U40) 
Laminar flow Heraeus (HS18 Hera safe) 
Light cycler Roche (LightCycler 1.5) 
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Equipment Supplier (Model) 
Light microscope Wild Heerbrugg (M5-51845) 
 Carl zeiss (Axiovert 25, invrted) 
 Olympus (CKX41, inveretd) 
Luminescent image analyzer GE healthcare (ImageQuant LAS 4000 mini) 
MACS smart strainers Miltenyi Biotec (130-098-462) 
Magnetic stirrer Janke & Kunkel GmbH (IKAMAG) 
Microtome Microm International GmbH (HM430) 
Leica RM 2125 RT 
Mini centrifuge Biozym (SPROUTTM) 
NanoDrop PeQlab BiotechnologieGmb (H ND-1000) 
Nitrogen tank Air Liquide (Arpege 140) 
Nucleofector® Amaxa (Nucleofector® II) 
Paraffin embedding system Leica (EG1120) 
PCR cycler Biometra (Thermocycler) 
Peristaltic pump TSE systems (Ismatec Reglo) 
pH meter Inolab (pH 720) 
Plate reader BIO-TEK (PowerWave XS) 
Power supply for gel chamber BIORAD (PowerPac HC) 
Radio telemetry DSI (PA-C10) 
Rotor gene Qiagen (Rotor gene Q) 
SDS-PAGE chamber BIORAD (Mini-Protean) 
Silicon block Flexi PERM (Sarstedt) 
Sonicator dr. hielscher GmbH (UP50H) 
Stereomicroscope Heerbrugg (Wild M650) 
Table top centrifuge Heraeus Pico 21 
Table top cooling centrifuge Hettich Zentrifugen Mikro22R 
Transfer chamber BIORAD Mini-Protean 
Transilluminator BIORAD Gel DocTM 
Universal power supply Biometra powerpack 
Vortex Scientific Industries Inc.Vortex-2 Genie 
Water bath Dinkelberg analytics E11 
2.3 Materials for surgery and ultrasound imaging 
Material Supplier (Ref no.) 
Anaesthetic pump Datex Ohmeda (Isotec5) 
Angiotensin II acetete Bachem (H-1705) 
Cannula B Braun Venofix®  (25G) 
Cannulation forceps F.S.T (11251-33) 
Deoxycorticosterone acetate (DOCA) Innovative Research of America (M121) 
Electrode cleanser  Dr. Schumacher GmbH (Cleanisept® wipes) 
Electrode gel Leonhard Lang GmbH (Skintact®) 
Eye cream Bayer (Bepanthen) 
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Material Supplier (Ref no.) 
Forceps and tweezers  F.S.T (Dumont, 11251-35)  
Hair removal cream Veet ultra (sensitive skin) 
Isoflurane Baxter (HDG9623) 
Microvessel clips Aesculap (FD562R)  
Osmotic mini pump Charles River Laboratories (Alzet, 1002) 
Physiologicla saline B. Braun 
Rectal lubricant  Parker laboratories (Aquagel®) 
Re-gel syringe DSI (276-0038-001) 
Remadyle (50mg/ml) Pfizer GmbH 
Silk F.S.T (18020-60) 
Skin antiseptic spray Schülke & Mayr GmbH (Kodan tinktur forte) 
Skin antiseptic cream Mundipharma GmbH (Betaisodona Salbe) 
Spring scissor (straight blade) F.S.T (15000-00) 
Surgical suture Ethicon (G-6, 30 cm 6-0 Perma-hand Seide) 
Syringe BD-plastipak (Luer-lokTM, 20 ml) 
Syringe BD-plastipak (Luer, 1 ml) 
Tissue glue 3MTM VetbondTM  
Ultrasound gel Dahlhausen (PZN 8825881) 
2.4 Chemicals and reagents 
Chemicals / reagents Supplier 
Agar Roth 
Agarose Sigma 
Ampicillin Sigma Aldrich 
APS Roth 
Bacto-tryptone BD 
Boric acid Sigma Aldrich 
Bio-Rad protein assay (Bradford)  BIORAD 
BSA Sigma 
Calcium chloride Merck 
Casein Sigma 
Calcium acetate Roth 
Chemiluminescence substrate LuminataTM  Forte (Merck Millipore) 
Collagenase Type 2 (Lot: 43D14200A) Worthingon 
Competent cells Invitrogen 
DABCO Sigma 
DAKO® pen Dako Denmark 
DAPI Invitrogen 
Disodium hydrogen phosphate Roth 
DNA ladder Thermo Scientific 
DTT Roth 
Deoxyribonuclease I Worthington 
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Chemicals / reagents Supplier 
EDTA AppliChem  
EGTA Roth 





Glycine Sigma Aldrich 
Glycerol VWR 
Hanks BSS Gibco 
HEPES Sigma 
KCl AppliChem 
LB-Broth Sigma (L3022) 
Leupeptin A Sigma 
L-glutamine 25030 Life technologies 
Loading dye Roti®-load 1Roth 
Lysis buffer Cytoskeleton 
Methanol Sigma Aldrich 
Methyl cellulose Sigma (M-0512) 
Mowiol 4-88 Fluka 
M-MLV reverse transcriptase Promega 
Nonidet-P-40 Fluka 
Oligo dT  Promega 
Paraformaldehyde Sigma 
Paraffin Paraplast® PlusTM Leica 
Pefabloc Fluka 
Penicillin Gibco 
Pepstatin A Sigma 
Polyacrylamide Roth 
Potassium dihydrogen phosphate Riedel- de Haën 
PBS Life technologies 
RNAlater (RNA stabilization reagent) Qiagen 
SOC medium Invitrogen 
SDS Serva 
Sodium fluoride Riedel- de Haën 
Sodium chloride Sigma Aldrich 
Sodium hydroxide Sigma Aldrich 
Sodium hydrogen carbonate J.T.Baker 




Triton-X 100 Sigma 
Taq polymerase Bioron 
Materials  18 
 
Chemicals / reagents Supplier 
Tris hydrochloride Roth 
Tween 20 Roth 
Xylene Sigma Aldrich 
Yeast extract Carl Roth 
Zinc acetate dihydrate Roth 
Zinc chloride Merck 
2.5 Kits 
Product Supplier (Catalog number) 
Basic nucleofector kit (SMC) Lonza (VPI-1004) 
DQ-gelatin Thermofisher (EnzCheck, D12054) 
Maxiprep kit Macherey-Nagel (740424.10) 
NucleoSpin® RNA extraction kit Macherey-Nagel (740955) 
Neonatal heart dissociation Kit Miltenyi Biotec (130-098-373) 
Neonatal cardiac fibroblast isolation Kit Miltenyi Biotec (130-101-372) 
QIAprep spin miniprep kit Qiagen (27104) 
QIAprep Plasmid midi kit Qiagen (12143) 
QuantiTect SYBR Green® kit Qiagen (204243) 
RNAeasy mini kit Qiagen (74104) 
Sensiscript RT kit Qiagen (205211) 
TOPO Mammalian Expression Vector Kit  Invitrogen (K36020) 
2.6 Oligonucleotides 
Gene Primer sequence  
Primers used for genotyping 
Zyxin WTR 5’ – TGGACGAAGTTTCCGTGTGTTG– 3’ 
Zyxin WTF 5’ – TACAAGGGCGAAGTCAGGGCGAGTG– 3’ 
Zyxin NEOF 5’ – GACCGCTTCCTCGTGCTTTAC– 3’ 
LPP Lacz F  
LPP Lacz R 
5’ – GCATCGAGCTGGGTAATAAGCGTTGGCAAT– 3’ 
5’ – GACACCAGACCAACTGGTAATGGTAGCGAC– 3’ 
LPP KOSB F 5’ – TTCCAGTTTCTCAGCTTAG– 3’ 
LPP KOSB R 5’ – CTGGACTATTGCTTGGTGAC– 3’ 
Primers used for cloning 
Zyxin F 5’ – GGCCATGGCGGCCCCCCGC– 3’ 
Zyxin R 5’ – TCAGGTCTGGGCTCTAGCGGAGTG– 3’ 
LPP F 5’ – GGCCATGTCTCACCCATCTTG– 3’ 
LPP R 5’ – CTACAGGTCAGTGCTTGCCT– 3’ 
Primers used for quantitative real time PCR 
Mouse  RPL32 
For 5’ – GGGAGCAACAAGAAAACCAA – 3’ 
Rev 5’ – ATTGTGGACCAGGAACTTGC -3’ 
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Human/mouse Gapdh For 5’ – GACCACAGTCCATGCCATCACTGC– 3’ 
Rev 5’ – ATGACCTTGCCCACAGCCTTGG– 3’ 
Mouse TRIP6 For 5’ – TACAAGTGTGAGGAGTGTGGG– 3’ 
Rev 5’ – TGAGAGCTCTTGGATACGCC– 3’ 
Mouse LPP For 5’ – ACCCTACAAGCCACGTCCCC 
Rev 5’ – GGTGGCTGCTGTGGAAT 
Mouse LOX For 5’ – CAGCCACATAGATCGCATGGT– 3’ 
Rev 5’ – GCCGTATCCAGGTCGGTTC– 3’ 
Mouse CTGF For 5’- CGAAGCTGACCTGGAGGAA–3’ 
 
Rev 5’ – TTGGCGATTTTAGGTGTC–3’ 
Mouse Col I α1 For 5’ – GAGCGGAGAGTACTGGATCG–3’ 
Rev 5’ – TACTCGAACGGGAATCCATC–3’ 
Mouse Col III α1 For 5’ – TGGTCCTCAGGGTGTAAAGG–3’ 
Rev 5’ – GTCCAGCATCACCTTTTGGT–3’ 
Mouse Itgb1 For 5’ – TGGCAACAATGAAGCTATCGTG–3’ 
Rev 5’ – GTAGGACAGTCTGGAGTCTCCACA–3’ 
2.7 Antibodies 
Antibody Application, Dilution, Supplier 
Primary antibody used in this study  
Rabbit polyclonal anti-zyxin, B71 WB, 1:1000  
ICC 1:250, Prof. Mary Beckerle, USA 
Rabbit polyclonal anti-PCNA IHC, 1:200, Abcam #ab2426 
Mouse monoclonal anti-beta actin WB, 1:5000,  Abcam #ab6276 
Rabbit polyclonal anti-tubulin WB, 1:1000, Cell signaling #2144 
Rabbit polyclonal anti-histone H3 WB, 1:3000, Abcam #ab1791 
Rabbit polyclonal anti-Ki67 IHC, 1:200, Abcam #ab16667 
Mouse monoclonal anti-LPP ICC, 1:200, Abcam # ab211682 
Rabbit polyclonal anti-LPP WB 1:1000, Atlas antibodies # HPA011133 
IHC, 1:200, Atlas antibodies # HPA011133 
Rabbit polyclonal anti-TRIP6, B65 WB 1:1000, Prof. Mary Beckerle, USA 
IHC, 1:200, B65, affinity purified 
Mouse monoclonal anti-SMA ICC, 1:200, Abcam # 7817 
Rabbit polyclonal anti-SMA ICC, IHC, 1:200, Abcam # 5694 
Rabbit monoclonal anti-calponin ICC, IHC, 1:200, Abcam # 46794 
Rabbit polyclonal anti-LOX ICC, IHC, 1:200, Abcam # 31238 
Rabbit monoclonal anti-GAPDH  WB, 1:5000, Cell signaling #2118 
Secondary antibody used in this study  
Cy2-conjugated donkey IgG (H+L) ICC 1:100 Dianova 
Cy3-conjugated donkey IgG (H+L) ICC 1:100 Dianova 
Cy5-conjugated donkey IgG (H+L) ICC 1:100 Dianova 
Rabbit Goat IgG peroxidase WB 1:5000 Sigma # A6154 
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Mouse Goat IgG peroxidase WB 1:5000 Sigma # A4416 
2.8 Growth media  
Media Purpose Composition 
Growth medium Isolation of VSMCs  DMEM (1x)  
+ GlutaMaxTM-I  
+ 5% FCS  
+Penicillin/Streptomycin/Fungizone 
Growth medium Propagation of VSMCs DMEM (1x)  
+ GlutaMaxTM-I  
+ 15% FCS  
+Penicillin/Streptomycin/Fungizone 
Growth medium Propagation of ACFs DMEM (1x)  
+ GlutaMaxTM-I  
+ 10% FCS  
+Penicillin/Streptomycin/Fungizone 
DMEM-methocell Spheroid preparation  1.2% Methyl cellulose 
+ DMEM (1x)  
+ GlutaMaxTM-I  
+ 30% FCS  
+Penicillin/Streptomycin/Fungizone 
Luria-Bertani (LB) agar  Propagation of bacteria 1.5 % (w/v) Agar in LB medium   
+ 50 μg/ml ampicillin 
Luria-Bertani (LB) medium Propagation of bacteria 1.0 % (w/v) Bacto-tryptone  
+ 0.5 % (w/v) Yeast extracts  
+ 1.0 % (w/v) NaCl 
2.9 Buffers and solutions 
Buffer Composition 
Blocking buffer for ICC/IHC 0.25 % Casein  
+ 0.1 % BSA  
+ 15 mM NaN3  
+ 50 mM Tris, pH 7.6 
Blocking buffer for WB 5 % milk powder or Blotto® in TBST 
Collagenase solution (Type 2) 2% (w/v) solution in PBS 
DNase I solution 0.5% (w/v) solution in PBS 
Lysis buffer (whole cell lysates) 10 mM HEPES, pH 7.9 
+ 10 mM KCl 
+ 0.1 mM EDTA 
+ 0.1 mM EGTA 
+ 0.1 M DTT 
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+ 50 µM Pefabloc 
+ 25 µM Protease inhibitors mix 
Lysis buffer I for nuclear extraction 10 mM HEPES, pH 7.9 
+ 10 mM KCl 
+ 0.1 mM EDTA 
+ 0.1 mM EGTA 
+ 0.15 % Nonidet-P-40 
Supplement fresh with 
+ 20 mM Na3VO4 
+ 15 mM NaF 
+ 1 mM DTT 
+ 1 mg/ml pefabloc 
+ 12 µg/ml Protease inhibitor mix 
Lysis buffer II for nuclear extraction 20mM HEPES 
+ 400 mM NaCl 
+ 0.01 mM EDTA 
+ 0.01 mM EGTA 
+ 0.15 % Nonidet-P-40 
Supplement fresh with 
+ 20 mM Na3VO4 
+ 15 mM NaF 
+ 1 mM DTT 
+ 1 mg/ml pefabloc 
+ 12 µg/ml Protease inhibitor mix 
Membrane stripping buffer 0.2 M NaOH 
Mounting medium for ICC/IHC 0.1 M Tris HCl, pH 8,5 
+ 10 % Mowiol 4-88 
+ 25 % Glycerin 
+ 2.5 % DABCO 
Phosphate-buffered saline (PBS) 8.0 g NaCl  
+ 0.2 g KCl  
+ 1.44 g Na2HPO4  
+ 0.2 g KH2PO4, in 1 liter H2O 
Pefabloc 15 mM HEPES buffer, pH 7,4 
+ 4 % Pefabloc-SC 
Protease inhibitor mix (PIM) 1 % Pepstatin-A in 20 % DMSO  
+ 80 % 15 mM HEPES, pH 7,4 
+ 1 % Leupeptin in 20 % DMSO 
Ringer’s solution 154 mM NaCl,  
+ 5.6 mM KCl  
+ 2.4 mM CaCl2,  
+ 6 mM NaHCO3  
+ 5.6 mM Dextrose,  
+ 30 mg/l Sodium nitroprusside 
Materials  22 
 
+ 27 mg/l Adenosine 
Running buffer for SDS-PAGE 25 mM Tris HCl, pH 8.3 
+ 192 mM Glycine 
+ 0.1% SDS 
5x TBE buffer 450 mM Tris  
+ 450 mM Boric acid  
+ 20 mM EDTA, pH 8.0 
Tris-buffered saline (TBS) 6.1 g Tris (0.5 M)  
+ 8.75 g NaCl (1.5 M) in 1 liter H2O  
TBST 0.05 % Tween-20 in TBS 
Transfer buffer 25 mM Tris HCl, pH 8.3 
+ 192 mM Glycine 
Zinc fixative 0.1 M Tris HCl, pH 7.4  
+ 3.2 mM Ca(CH3COO)2(H2O)  
+ 22.8 mM Zn(CH3COO)2.2H2O 
+ 35.9 mM ZnCl2 
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3 Methods 
3.1 Animal experiments 
All animal studies were performed with permission of the Regional Council Karlsruhe and in 
conformance with the Guide for the Care and Use of Laboratory Animals published by the US 
National Institute of Health (NIH publication No. 85-23, revised 1996). C57Bl6/J wild type (WT) mice 
were purchased from Charles River laboratories. Zyxko110 and Lppko103 mice (at least 10 times back 
crossed on the C57Bl6/J background) were bred and housed in the Interfaculty Biomedical Facility 
(IBF) of Heidelberg University. Mice were housed in plastic cages with hard wood chips as bedding, 
under controlled conditions of 12 hour dark-light cycles. They all received standard pellet diet and 
water ad libitum. Mice were euthanized in CO2 chambers. 
3.2 Methods using isolated cells 
3.2.1 Cell isolation and culture 
3.2.1.1 Isolation of mouse vascular smooth muscle cells (VSMCs)  
To isolate the mouse VSMCs, the thoracic aorta was isolated, cleared from surrounding fat and cut 
into small fragments. After washing with Hank's Balanced Salt Solution (HBSS), these fragments were 
transferred to one well of a 6-well plate containing 1.4 ml of SMC growth medium (DMEM: SMC 
growth medium 2 in 1:1 ratio) supplemented with 5% FBS and containing 250 µl collagenase solution 
(1%). The arterial fragments were incubated overnight at 37 °C for better digestion and the medium 
was replaced with fresh SMC growth medium without collagenase on next day. Upon reaching the 
70-80% of cell confluency, the cells were trypsinized and centrifuged for 5 minutes at 1000 rpm. The 
cell pellet was suspended in DMEM medium containing 15% FCS, antibiotics and fungicide for 
further propagation and experimentation. 
3.2.1.2 Monolayer culture of VSMCs (2D cell culture) 
Isolated VSMCs were seeded in T25 or T75 flasks and propagated with DMEM containing 15% FCS 
and supplemented with antibiotics and fungizone. For the experiments, cells were either seeded on 
plastic plates or collagen type I-coated BioFlex® culture plates. Cells were allowed to grow in a CO2 
incubator (5%) at 37 °C. Cells cultured up to maximum three passages were used for the experiments 
to avoid artifacts due to prolong sub-culture of smooth muscle cells.  
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3.2.1.3 Culturing of VSMCs in 3D spheroid 
DMEM with 30% FCS containing antibiotic and fungizone was mixed with methylcellulose (stock, 
1.2% methylcellulose in DMEM basal medium) in a ratio of 4:1112. To form spheroid, VSMCs were 
seeded in U-bottom 96-well plates (3000 cells/well) in DMEM-methylcellulose medium and 
incubated O/N at 37 °C. Cell spheroids were further allowed to grow for 48 hours prior to harvest for 
specific purposes. 
3.2.1.4 Isolation and culture of cardiac fibroblast from adult mouse heart  
For isolation of adult cardiac fibroblasts (ACFs), the heart was isolated from euthanized animal and 
the atrium was removed. The remaining ventricular parts of the heart were washed several times 
with cold PBS to remove red blood cells and cell debris. The heart was chopped in fine pieces and 
incubated with the digestion solution from neonatal heart dissociation kit for 10 min at 37 °C 
without shaking. From this digested heart, single cell suspension was prepared by using GentleMACs 
dissociator. After sieving the cell suspension from any undigested part, the cell pellet was collected 
by centrifuging. This cell pellet was then sorted for cardiac fibroblast by magnetic-activated 
cell sorting (MACS) using neonatal cardiac fibroblast isolation kit  according to the provided protocol.  
Isolated ACFs were then seeded in a gelatin coated 6-well plate with DMEM medium containing 10% 
FCS and antibiotics. ACFs were allowed to grow till 70-80% confluency and used within 3-5 days.  
3.2.2 Biomechanical stretch protocol  
According to Laplace’s law, wall tension in a blood vessel is dependent on transmural pressure, 
radius of the vessel and wall thickness. As it is difficult to expose cultured VSMCs to a transmural 
pressure gradient, an easier, reproducible way of mimicking wall tension in vitro is to increase its 
radial component. Biochemical stretch method is routinely used to mimic an increase in 
circumferential wall tension during hypertension55,113. VSMCs were seeded on collagen I-coated 
BioFlex® culture plate and were exposed to 15% cyclic elongation at 0.5 Hz with a sinusoidal profile 
using a Flexercell®FX-5000TM strain unit for specific time periods depending on the experimental 
design. However, cyclic stretch generated in this model is not a reflection of the pulsatile nature of 
blood flow in the body.  
3.2.3 Transfection 
A NucleofectorTM technology (LONZA) was used for transient transfection of expression plasmids in 
VSMCs according to the manufacturer’s instructions. 2x106 cells were transfected with 4 µg of 
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plasmid DNA using the preset program U025 for primary smooth muscle cells. A GFP expressing 
construct (Lonza) was used as a control for all transient transfection experiments. After 48 hours of 
transfection, the cells were analyzed. The transgenic expression was confirmed by 
immunofluorescence and Western blot analysis. 
3.2.4 Immunofluorescence (IF) analysis 
3.2.4.1 Fixation and IF analysis of monolayer 2D culture of VSMCs  
Cells were either fixed with 4 % PFA (15 min, at room temperature, RT) or ice cold methanol (10 min, 
at –20 °C) depending on the experiment. The fixed cells were permeabilized with 0.1% Triton X-100 
for 10 minutes and incubated with casein blocking solution for 30 minutes. Thereafter, cells were 
incubated with primary antibodies (diluted in the blocking solution) for 2 hours at RT or overnight at 
4 °C. The cells were washed with PBST to remove excess unbound antibodies and incubated with 
secondary antibodies (conjugated with Cy2, Cy3, Cy5) for 1 hour at RT. After washing with PBS, the 
cells were incubated with nuclear staining dye DAPI (4', 6-diamidino-2-phenylindole) for 5 minutes, 
washed with PBS and mounted on cover slips with mowiol. Images were obtained using an IX81 
confocal microscope equipped with a IX-DSU disk unit and analyzed with ImageJ. 
3.2.4.2 Fixation, paraffin embedding and IF analysis of 3D spheroid culture of VSMCs  
After 48 hours of culturing (3000 cells/spheroid), spheroids were harvested and fixed with zinc 
fixative for O/N at 4 °C. Subsequent rehydration steps were followed by serial incubation in 70%, 
85%, 96% ethanol and isopropanol and finally embedded in the paraffin wax112. The paraffin 
embedded spheroids were sectioned in 5 µm thickness and deparaffinized after O/N drying at 37 °C. 
Deparaffinized spheroid sections were then incubated with blocking buffer and finally with primary 
antibody for 2 hour at RT or overnight at 4 °C. After washing off the nonspecifically bound primary 
antibody, fluorescent probes conjugated secondary antibodies were incubated for 1 hour at RT. 
Finally, the spheroid sections were mounted with mowiol using cover slips. Images were taken with 
IX81 confocal microscope and analyzed with the ImageJ.  
3.2.5 Molecular biology methods 
3.2.5.1 Isolation of RNA from cultured cells 
Total RNA was isolated using a RNA extraction kit according to manufacturer’s instructions. Cells 
were briefly washed with ice-cold Hanks PBS solution and lysed with 350 µl lysis buffer containing 
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1% β-mercaptoethanol. The RNA was eluted in 30-35 µl of RNase-free water. The concentration and 
quality of the RNA was determined using a spectrophotometer (NanoDrop ND-1000). 
3.2.5.2 Reverse transcription 
Reverse transcription of the isolated RNA was carried out using Omniscript RT Kit according to the 
supplied protocol. Briefly, 500 ng of the RNA template and 0.1 M Moloney murine leukemia virus 
reverse transcriptase (M-MLV RT) were mixed with oligo dT primer in a volume of 20 µl and 
incubated at 42°C for 50 minutes for first strand cDNA synthesis. The resultant cDNA (20 µl) was 
diluted 1:5 or 1:10 with Dnase-free water for conventional and real time PCR, respectively. 
3.2.5.3 Standard PCR 
Standard PCR has been used to amplify gene sequences for cloning or mice genotyping.  The PCR 
reaction mixture (containing cDNA, dNTP, MgCl2, taq-polymerase with 10x reaction buffer in 50 µl 
volume) was placed in an automatic thermocycler.  
3.2.5.4 Quantitative real time polymerase chain reaction (real time PCR) 
Real time PCR was performed by using the QuantiTect SYBR Green® kit. Briefly, 5 µl cDNA, 1 µl each 
of forward and reverse primers (10-20 µM), 3 µl of RNase-free water, and 10 µl of SYBR Green were 
added to obtain a final reaction volume of 20 µl. Different annealing temperatures were used for 
specific primer pairs. The quantification of changes in gene expression was done using the (delta) 
(delta) Ct method114(based on the number of cycles required for crossing a certain threshold of 
detection). Expression levels of all the experimental genes were normalized using the reference gene 
RPL32 (60S ribosomal protein L32). 
3.2.5.5 Expression plasmids 
For mouse zyxin expression plasmid, a full-length PCR fragment including the first stop codon 
(positions 305 to 1999; NM_011777, from cDNA prepared from VSMCS) was sub-cloned into the 
pcDNA™6.2/N-EmGFP-GW TOPO® 5.9-kb vector, with the TOPO cloning reaction according to the 
manufacturer’s recommendations. For the mouse LPP expression plasmid, the same principle was 
used with a full length PCR fragment including the first stop codon (Positions 551 to 2392; 
NM_178665.5, from cDNA prepared from VSMCS). Positive constructs were sequenced and used for 
transient overexpression experiments. In both cases, 2 µl of the TOPO vector containing the PCR 
fragment was transformed in Top10FTM competent bacterial cells. 50 and 100 µl of transformed 
Methods  27 
 
bacterial cells were plated on sterile LB-agar plates with ampicillin. Bacterial colonies were allowed 
to grow overnight at 37 °C. Transformed colonies were randomly picked and inoculated in LB 
medium with antibiotics and let them grow overnight at 37 °C with shaking. Plasmids were purified 
using the QIAPrep® Spin Miniprep kit according to manufacturer’s instructions. The proper 
orientation of the insert was verified by restriction digestion and sequencing. For the correct 
plasmids, the corresponding bacterial colonies were further propagated and a concentrated plasmid 
DNA was prepared by QIAPrep® Maxiprep kit. 
3.2.6 Biochemical methods 
3.2.6.1 Total protein extraction 
Cells were washed with ice-cold HBSS and 100 µl of whole cell lysis buffer was added to each well of 
a 6-well plate. Cells were then scraped off and collected into 1.5 ml tubes placed on ice. 2.5 µl of 
Triton X-100 was added for each 50 µl of lysis buffer and incubated for 10 minutes. The resulting 
lysate was centrifuged at 12,000g for 15 minutes at 4 °C to remove any debris. The lysate was 
either snap frozen and stored at -80 °C or used for further analysis. The protein concentration was 
measured using a Bradford assay (Bio-Rad) with a colorimetric plate reader.  
3.2.6.2 Nuclear protein extraction 
To determine the sub-cellular localization of proteins, the cell lysate was separated into cytosolic 
and nuclear fractions58. VSMCs were lysed using lysis buffer I for nuclear extraction. The lysates were 
centrifuged (12,000g at 4 °C for 15 minutes) and the supernatant (cytosolic fraction) was collected. 
The residual pellet containing the nuclear fraction was washed twice with ice-cold Hanks buffer, 
dissolved in 40 μL lysis buffer II and sonicated 2 times for 5 seconds at 50 Watts on ice. After 
centrifugation (12,000g at 4 °C for 15 minutes), the supernatant containing the nuclear fraction was 
collected. 
3.2.6.3 Immunobloting 
Protein samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Separating gels were prepared depending on the size of the proteins of interest. Proteins 
were denatured by addition of sample loading buffer followed by heating at 95°C for 10 minutes. 
The proteins were then separated in gel and transferred into a PVDF membrane (pre-activated with 
methanol, 10 minutes at RT). After the transfer, the membrane was incubated with blocking buffer 
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for 1 hour, followed by incubation with primary antibody overnight at 4 °C.  After brief wash of 
membrane with TBST, secondary antibody (conjugated to horseradish peroxidase) incubation was 
done for 1 hour at room temperature. Finally, the membrane was washed with TBS and the proteins 
were detected by chemiluminescence based method using an ‘ImageQuant LAS 4000 mini’ imaging 
system. Densitometric analysis was done with the help of ImageJ. 
3.2.7 Functional assays using cultured cells 
3.2.7.1 Migration analysis by wound healing assay in 2D cell culture of VSMCs 
Mouse VSMCs (5×104 cells/well) were seeded in 12-well plastic plates with a silicon block in the 
middle of the well. Upon reaching the cell confluency around 70-80%, the silicon block cell growing 
hindrance was gently removed. Light microscopic images were taken at the beginning and 24 hours 
later (at same spots on both days). The distance between the cell borders was measured by ImageJ. 
3.2.7.2 Proliferation assay by counting DAPI-positive nuclei in 2D cell culture of VSMCs 
VSMCs isolated from same animal were seeded in two 6-well plastic plates (2×104cells/well) and 
allowed to attach (6 hours). Immediately after attachment, the cells in one plate were fixed (T0) 
while the other was fixed 72 hours (T72) after the attachment. Cells were fixed with 4 % PFA and 
stained with DAPI.  Images were taken and analyzed with ImageJ.  
3.2.7.3 Migration by spheroid invasion assay in 3D cell culture of VSMCs 
A modification of the spheroid angiogenesis assay was used to measure the invasion of VSMCs into a 
collagen gel as previously described112,115. To form spheroid, VSMCs were seeded in U-bottom 96-
well plates (500 cells/well) in growth medium containing methylcellulose and incubated O/N at 37 
°C. The spheroids were then suspended into a gel containing rat tail collagen-type-I and 1 ml of the 
resultant mixture was plated in one well of a 24-well plates and allowed to polymerize at 37 °C for 
30 minutes. 100 µL of DMEM medium (containing 30% FCS) was added over the gel surface. 24 
hours later light microscopic images of the spheroids were taken and the number of sprouts and 
cumulative length was measured. For each genotype, at least 20-25 spheroids were analyzed per 
experiment. 
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3.2.7.4 Analysis of proliferation and contractile properties of VSMCs in 3D cell culture  
To study the proliferation nature of the VSMCs in 3D spheroid culture, the paraffin embedded 
spheroid sections (5 µm thick) were immunoflurescently labeled with Ki67 and DAPI.  From captured 
confocal images Ki67-positive DAPI nucleus were counted. For contractile properties of the VSMCs in 
3D spheroid culture, sections were stained for alpha smooth muscle actin (α-SMA), calponin and 
DAPI.  
3.2.7.5 Analysis of matrix metalloproteinases (MMP) activity of VSMCs in 2D and 3D cell 
culture 
MMP activity was measured in the fixed cells by DQ-gelatin assay (EnzChek). Normally, in DQ-gelatin, 
the fluorescence intensity is intramolecularly quenched and can be revealed after proteolytic 
degradation (Figure 3.1). In 2D monolayer cell culture, VSMCs were serum starved for 24 hours and 
fixed with ice cold methanol at -20°C.  Fixed cells were then incubated with DQ-gelatin at 37 °C for 1 
hour. Thereafter, these cells were further immunostained with either MMP9 or MMP2. Zinc fixed 
paraffin embedded spheroid sections were incubated with DQ-gelatin at 37 °C for 2 hours and 
further stained for either MMP9 or MMP2116. Nucleus was counter stained with DAPI. 
 
Figure 3.1 Principle of MMP activity detection via DQ-gelatin assay 
The degree of MMP activity is determined by the extent of fluorescence intensity revealed upon hydrolysis of the 
labeled and quenched substrate provided in the DQ-gelatin assay kit. 
3.3 In vivo methods 
Experimental hypertension was induced in WT, Lppko and Zyxko mice to study the remodeling 
processes in the heart and vasculature. All animal experiments were approved by the local ethics 
committee (Ethics approval G 217/14 and G 60/15). 
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3.3.1 Induction of experimental hypertension 
3.3.1.1 Induction of hypertension by DOCA-salt  
The DOCA-salt model is a renovascular volume-overload model which induces an increase in blood 
pressure by retention of sodium and water in the kidneys117. Briefly, 3 months old (young) WT and 
Lppko mice were anaesthetized using isoflurane. After removing the hair from  back, the skin was 
disinfected and a small incision was made for a paravertebral pocket. The DOCA-salt pellet (50 mg) 
was placed inside the pocket. The pellets contained a biodegradable matrix which released the 
active ingredient in a sustained manner over a period of 21 days. The incision was closed with 
sutures and the animal was allowed to regain consciousness. The body temperature of the animal 
was maintained at 37 °C during the entire procedure. In order to complement the effect of DOCA-
salt on blood pressure, the drinking water was supplemented with 1% w/v (Figure 3.2) 
 
Figure 3.2 Schematic representation of the DOCA-salt model used to induce experimental 
hypertension and the subsequent analyses performed  
(A) Protocol for the blood pressure measurement. (B) Experimental design to measure cardiac function and the 
resistivity index in the DOCA-salt treated animals. Abbreviations: BP, blood pressure; RI, resistivity index. Each 
double headed arrow represents a period of seven days. 
3.3.1.2 Induction of hypertension by angiotensin II  
Aged matched WT and Zyxko mice were anaesthetized using isoflurane. After removing the hair and 
disinfecting the skin, a paravertebral pocket was created towards the head between the subcutis 
and the fasciae of the back muscles. The osmotic mini pump filled with Ang II (in a dose of 1.5 
mg/kgBW/day, stock was diluted in 0.9% NaCl for specific body weight) was placed in the pocket. 
The incision was closed with sutures and the animal was allowed to regain consciousness. The body 
temperature of the animal was maintained at 37 °C during the entire procedure (Figure 3.3). 
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Figure 3.3 Schematic representation of the angiotensin II model to induce experimental 
hypertension and the subsequent analyses performed  
Physiological saline solution (0.9%, w/v, NaCl) was used as vehicle control for the treatment with angiotensin II. 
Abbreviations: Ang II, angiotensin II; BP, blood pressure. Each double headed arrow represents a period of seven 
days. 
3.3.2 Blood pressure measurements in mice 
3.3.2.1 Telemetry 
Arterial blood pressure was monitored using radio telemetry probe (PA-C10, DSI) placed at the aortic 
arch through the left common carotid artery. Briefly, the pain reflex of the isoflurane (1-3% v/v) 
mediated anaesthetized mouse was tested and the limbs were fixed with tape. The hair was 
removed from the throat region prior to skin disinfection. The animal was slightly stretched for 
better visualization of the carotid arteries by placing a thread to the upper incisors. After skin 
incision, the salivary glands and left common carotid artery were carefully separated from the 
surrounding fats, nerves and veins. A permanent cranial ligature was placed just below the 
bifurcation of the carotid artery and a caudal occlusion was made with a micro-vessel clip to 
temporarily stop the blood flow in this artery segment. The probe was inserted into the artery 
through a delicate incision and made sure that the tip reached the arch of the aorta and was 
exposed to the circulating blood. The battery unit of the device was placed in a subcutaneous pocket 
in the lateral left flank of the mouse. The skin incision was closed and the animal was allowed to 
regain consciousness. The complete surgical procedure was carried out by placing the mouse on a 
heating plate at 37 °C.  The operated animal was placed inside the cage and kept warm by exposing 
infra-red light for at least 1 hour. After 7-8 days of post-operative recovery stage, baseline blood 
pressure was recorded for five days. DOCA (deoxycorticosterone acetate)-salt pellets were 
implanted afterwards and blood pressure was monitored for next 21 days (Figure 3.2). 
3.3.2.2 CODA® tail-cuff method 
The tail-cuff method is a non-invasive method for blood pressure measurement in mice. The CODA® 
tail-cuff system was designed to accurately measure blood pressure in the mouse by utilizing volume 
pressure recording (VPR) sensor technology to detect the changes in tail volume that correspond to 
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systolic and diastolic pressures. The mouse was inserted into a small restrainer and placed on a 
warm platform to comfortably house the mouse while minimizing the movement during the 
measurement session. The darkened nose cone of the restrainer limit the mouse’s view and 
decreased the level of stress. The rear of the restrainer with the mouse tail was extended outward. 
The CODA non-invasive blood pressure system relies on two tail cuffs to measure blood pressure, 
occlusion cuffs (O-cuff) and volume pressure recording cuffs (VPR-cuff). During the measurement 
cycle, the VPR-cuff inflates first to push blood out of the tail. The O-cuff inflated first to block blood 
flow back into the tail. The VPR cuff deflates to 30 mmHg pressure to remain snug around the tail to 
detect changes in tail volume. As the O-cuff deflates and the systolic blood pressure exceeds the O-
cuff pressure, blood will flow into the tail and the VPR cuff will detect the increase in tail volume. 
The O-cuff pressure at the point when tail volume increases is the systolic blood pressure. O-cuff 
continues to deflate, and the pressure at the point when the rate of tail volume change no longer 
increases is the diastolic blood pressure. This non-invasive blood pressure measurement protocol 
can measure systolic, diastolic, and mean arterial blood pressure, heart rate, tail blood volume and 
blood flow. For each animal, 15 blood pressure reading cycles were performed and recorded (first 5 
for acclimatization and the following 10 for regular cycle). Blood pressure recorded in the regular 
cycle was then used for subsequent analysis.  
3.3.3 High resolution ultrasound measurements in mice 
3.3.3.1 Echocardiographic image recoding and cardiac function analysis 
For cardiac systolic and diastolic function analyses, VisualSonics Vevo 2100 imaging system equipped 
with MS-550D micro scan transducer (40 MHz) was used to record high resolution ultrasound 
images. The animal was anaesthetized with isoflurane (1-3% v/v) and positioned on heating platform 
at supine position. Electrocardiogram (ECG), respiration and body temperature was continuously 
monitored during the recoding of the images. After removing hair from the chest area, a generous 
amount of warm ultrasound-compatible gel was applied to record the images. 
The morphology and the systolic function of the heart were analyzed in the parasternal long axis 
view (PLAX). Images were taken in the brightness mode (B-mode) and the motion mode (M-mode). 
Anatomical structures were identified in B-mode which displayed two-dimensional images of an area 
of interest. In the M-mode, the movement of the sample volume (vertical line in B-mode) over time 
was displayed (Figure 3.4 A). The images were analyzed using the analysis software from 
VisualSonics (Figure 3.4 B). The measurements available in the M-mode include the left ventricular 
(LV) anterior wall thickness during systole and diastole, LV internal diameter in systole and diastole, 
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LV posterior wall thickness in systole and diastole, intraventricular septum thickness in systole and 
diastole. Based on these parameters, the software uses inbuilt algorithms to calculate ejection 
fraction, fractional shortening, stroke volume and cardiac output of the heart. 
 
Figure 3.4 Echocardiographic image recoding and cardiac systolic function analysis 
(A) Representative echocardiographic image in the parasternal long axis view (PLAX) in M-mode. (B) 
Measurement of cardiac systolic functional parameters e.g. cardiac output (CO), fractional shortening (FS), 
ejection fraction (EF), and stroke volume (SV) from the recoded M-mode image. The bottom trace shows the 
simultaneously recorded electrocardiogram.    
The diastolic function of the heart was analyzed in the apical four chamber view (Figure 3.5 A). 
Images were recorded in color and pulse wave (PW) Doppler mode. In color Doppler mode, the 
direction of the blood flow was visualized. In PW Doppler mode, velocity of blood flow, which is 
visualized in color Doppler mode imaging, were measured. For this purpose, the sample volume 
(square) is placed above the mitral valve and the blood flow was visualized using the color Doppler 
mode. Using the PW Doppler mode, the velocity for the passive filling of the ventricle (E value) and 
the active filling of ventricle (A value) were measured (Figure 3.5 B). In addition, the E/A ratio, a 
common indicator of diastolic function was calculated.  
3.3.3.2 Measurement of resistivity index of femoral arteries by ultrasound imaging  
The resistivity index (RI) is an important parameter which is determined from the arterial pressure 
waveform visualized in PW Doppler ultrasonography.  To measure the RI towards the blood flow in  
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Figure 3.5 Echocardiographic image recoding and cardiac diastolic function analysis  
(A) Recorded echocardiographic image in the apical four chamber view in B-mode with the area of view placed 
over the mitral valve. (B) Measurement for the early passive (E) and late active (A) filling velocities of the left 
atrium in the Pulse Wave Doppler mode. Abbreviations: SW, intraventricular septal wall; RV, right ventricle; LV , 
left ventricle; MV, mitral valve; TV, tricuspid valve; RA, right atrium; LA, left atrium. 
   
Figure 3.6 Measurement of resistivity index of the femoral arteries by ultrasound imaging 
(A) Color Doppler image to locate blood flow in the femoral artery of the mouse. Blood flowing towards the 
transducer is represented by red and the blood flowing away from the transducer is represented by blue. (B) 
Measurement of the peak systolic velocity (PSV) and end diastolic velocity (EDV) in the left femoral artery.   
the femoral arteries by ultrasound imaging, the animal was prepared on the platform as previously 
described (section 3.3.3.1). Hair was removed from the hip and the groin region down the left hind 
limb. A generous amount of warm ultrasound-compatible gel was applied and MS-770D micro scan 
transducer (70 MHz) head was placed parallel to the femoral artery. The position of the transducer 
was fine-tuned by using the B-mode and the femoral artery and the vein were distinguished by color 
Doppler mode (Figure 3.6 A). Blood flowing towards the transducer is represented by red and the 
blood flowing away from the transducer is represented by blue and in this case representing the vein 
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and artery, respectively. To acquire the images, the transducer probe was placed in an angle of 45 
to the blood flow. The peak systolic velocity and the end diastolic velocities were measured with 
Vevo 2100 analysis software (Figure 3.6 B). These values were used to calculate the resistivity index 
(RI) using the formula:  (Peak systolic velocity – End diastolic velocity)/ Peak systolic velocity. 
3.4 Histochemical methods 
3.4.1 Tissue preparation  
In euthanized mice, retrograde perfusion was done with ringer solution by puncturing the heart in 
the left ventricle. Excised organs, after weighing, were preserved according to the subsequent 
analyses planned, i.e. heart tissue fixed in 4% PFA and isolated femoral artery in zinc fixative. After 
fixation, tissue samples were dehydrated using a series of increasing concentrations of ethanol (70, 
85 and 99%) followed by incubation in Isopropanol. Thereafter, the tissues were embedded in 
paraffin blocks and stored at room temperature. A fine section of the tissues (5 µm in thickness) 
were dried and immobilized on the glass slides by drying at 42 °C overnight.  
3.4.2 Histological staining 
Masson’s trichrome and van Gieson’s staining protocol were used for the detection of collagen fibers 
in the heart. The specimens were mounted with a resinous mounting medium (Eukitt®) and imaged 
using a light microscope. In Masson trichrome staining, collagen stained blue, nuclei appeared black 
and muscle and cytoplasm appeared red whereas in van Gieson’s staining collagen appeared pink, 
nuclei appeared black and the heart muscle appeared yellow. Slide stained with van Gieson’s 
protocol were analyzed by two blinded persons for the experiment under microscope to calculate 
the fibrotic score without any biasness. Fibrotic scale was adapted from Beggah et al118. Scoring was 
performed as 0, no collagen at all; 1, only around the blood vessels; 2, at least 2 area of collagen 
deposition in cardiac tissue; 3, at least 4 area of collagen deposition in cardiac tissue; 4, at least 6 
area of collagen deposition in cardiac tissue; 5, more than 6 area of collagen deposition in cardiac 
tissue118.   
3.4.3 Immunohistochemistry  
Prior to immunostaining, the paraffin sections were deparaffinized and rehydrated. Heat mediated 
antigen retrieval steps were done using steam cocker with 0.1 M citrate buffer at pH 6 for the PFA-
fixed samples. The tissue samples were encircled with a DAKO pen by drawing a water repelling 
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circle around the specimen. Thereafter, the same process of immunostaining was performed as 
described in section 3.2.4.2. 
3.4.4 RNA isolation and cDNA preparation from tissues 
Excised tissues were immediately placed in RNA later stabilization reagent (Thermofisher Scientific) 
for overnight. Tissues were homogenized in lysis solution with gentle MACs dissociator. A RNeasy® 
mini kit was used for isolating RNA according to manufacturer’s instructions from the tissue lysates. 
Sensiscript® reverse transcription kit was used to synthesize the cDNA from purified RNA according 
to manufacturer’s instructions.  
3.4.5 Protein isolation from tissues 
After tissue isolation, the samples were snap frozen and stored at -80 °C prior to use. The tissues 
were lysed with RIPA buffer containing a cocktail of protease inhibitor mixture (PIM), pefabloc® 
(Roche), sodium orthovanadate and sodium fluoride. Lysate was then cleared by centrifuging at 
12,000 rpm at 4 °C for 15 minutes. The supernatant was collected, snap frozen and stored at -80 °C 
for further protein analysis. 
3.5 Image analysis  
All the acquired images were post processed and analyzed with ImageJ 
(https://imagej.net/Fiji/Downloads). To measure the fluorescence intensity of labeled protein, same 
threshold was used in 8-bit images. To count the nucleus number, batch command was recorded 
(with specific threshold for 8 bit image and circularity parameter to determine the shape for 
nucleus) and used. To analyze the fibrotic area in the heart section, randomly numbered images 
were analyzed by the blinded person for the experiment to record an ImageJ macro which was then 
further used. 
Script of the macro to measure the fibrotic area was as follows  
if (isOpen("Results")), {selectWindow("Results"); run("Close");}; run("Set Scale...", "distance=0"); run("Set 
Measurements...", "area redirect=None decimal=3"); run("Duplicate...", "title=RGB"); 
getRawStatistics(count,mean1,min,max,std1); run("Split Channels"); selectWindow("RGB (red)"); close(); 
selectWindow("RGB (green)"); setAutoThreshold("Triangle dark");//condition1 setOption("BlackBackground", false); 
getThreshold(lower1,upper1); if(abs(mean1-lower1)<10){}else{setAutoThreshold("Moments 
dark");//condition1setOption("BlackBackground", false); getThreshold(lower2,upper2); setThreshold(lower2-
100/abs(mean1-lower1),255); setOption("BlackBackground", false);}run("Convert to Mask");run("Create Selection");//CS 
run("Make Inverse"); roiManager("Add"); roiManager("Select", 0); roiManager("Rename",  fibrosis1"); selectWindow("RGB 
(blue)"); run("Gaussian Blur...", "sigma=2"); setAutoThreshold("Default dark");//condition 2 setOption("BlackBackground", 
false); run("Convert to Mask"); run("Create Selection"); run("Make Inverse"); roiManager("Add"); roiManager("Select", 1); 
roiManager("Rename", "tissue1"); close(); close(); run("Select None"); run("Duplicate...", "title=RGB"); 
roiManager("Select", 0); run("Multiply...", "value=0.000"); roiManager("Select", 1); run("Make Inverse"); run("Multiply...", 
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"value=0.000"); run("Split Channels"); imageCalculator("Subtract create", "RGB (green)","RGB (blue)"); 
selectWindow("Result of RGB (green)"); setAutoThreshold("Triangle dark");//condition 3 setOption("BlackBackground", 
false); run("Convert to Mask"); run("Create Selection"); roiManager("Add"); roiManager("Select", 2); 
roiManager("Rename", "muscle1"); close(); selectWindow("RGB (blue)"); close(); selectWindow("RGB (green)"); close(); 
selectWindow("RGB (red)"); close(); run("Select None"); run("Duplicate...", "title=RGB"); roiManager("Select", 2); 
run("Multiply...", "value=0.000"); run("Split Channels"); imageCalculator("Subtract create", "RGB (red)","RGB (blue)"); 
selectWindow("Result of RGB (red)"); setAutoThreshold("IJ_IsoData dark");//condition4 setOption("BlackBackground", 
false); run("Convert to Mask"); run("Create Selection"); roiManager("Add"); roiManager("Select", 3); 
roiManager("Rename", "fibrosis2"); roiManager("Select", newArray(0,3)); roiManager("Combine"); roiManager("Add"); 
roiManager("Select", 4); roiManager("Rename", "fibrosis"); roiManager("Select", newArray(1,2,4)); 
roiManager("Combine"); roiManager("Add"); roiManager("Select", 5); roiManager("Rename", "tissue"); close(); 
selectWindow("RGB (blue)"); close(); selectWindow("RGB (green)"); close(); selectWindow("RGB (red)"); close();  
roiManager("Select", 0); roiManager("Delete"); roiManager("Select", 0); roiManager("Delete"); roiManager("Select", 0); 
roiManager("Delete"); roiManager("Select", 0); roiManager("Delete"); roiManager("Select", 1); run("Create Mask"); 
rename("Mask1"); run("Fill Holes"); run("Outline"); setOption("BlackBackground", false); run("Dilate"); run("Dilate"); 
run("Dilate"); roiManager("Select", 0); run("Create Mask"); rename("Mask2"); imageCalculator("Multiply create", 
"Mask1","Mask2"); selectWindow("Result of Mask1"); imageCalculator("Subtract create", "Mask2","Result of Mask1"); 
selectWindow("Result of Mask2"); run("Create Selection"); roiManager("Add"); close(); selectWindow("Result of Mask1"); 
close(); selectWindow("Mask2"); close(); selectWindow("Mask1"); close(); roiManager("Select", 0); roiManager("Delete"); 
roiManager("Select", 1); roiManager("Rename", "fibrosis"); rename("raw"); run("Select None"); run("Duplicate...", 
"title=tissue"); run("Duplicate...", "title=fibrosis"); selectWindow("tissue"); roiManager("Select", 0); run("Multiply...", 
"value=0.000"); selectWindow("fibrosis"); roiManager("Select", 1); run("Multiply...", "value=0.000"); run("Images to Stack", 
"name=Stack title=[] use"); run("Make Montage...", "columns=3 rows=1 scale=1 border=0 label"); selectWindow("Stack"); 
roiManager("Select", 0); roiManager("Measure"); roiManager("Select", 1); roiManager("Measure"); run("Select None"); 
setResult("Area", 2, getResult("Area",1)/getResult("Area",0)); setResult("Label", 2, "ratio of fibrosis"); setResult("Label", 0, 
"area of tissue"); setResult("Label", 1, "area of fibrosis"); 
3.6 Statistical analysis 
Data were analyzed by GraphPad Prism7 (GraphPad Software). All the results were represented as 
means ± SEM of mentioned number of individual mice. For analyzing differences between two 
individual experimental groups, an unpaired Student’s t test was used with P<0.05 considered 
statistically significant. Differences among 3 or more experimental groups were analyzed by one-way 
ANOVA, followed by a Tukey’s multiple comparison test for selected pairs of groups with a 
probability value of P<0.05 considered statistically significant. 
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4 Results 
4.1 Abundance of zyxin family members in the femoral artery of Zyxko mice 
Age-dependent variation of the level of two closely related members of the zyxin family of LIM-
domain-containing proteins, TRIP6 and LPP, in selected arterial blood vessels of Zyxko mice was 
determined by RT-qPCR and WB analyses.  
4.1.1 Expression (mRNA levels) of TRIP6 and LPP in the femoral artery 
In wild type animals, the fold change in TRIP6 and LPP mRNA expression remained similar at the time 
points studied (6 and 12 months versus the 3 months reference level). In Zxyko mice, mRNA for both 
gene products peaked at 12 months and then returned to baseline in the 18 months old animals 
(Figure 4.1 A, B). 
 
Figure 4.1 TRIP6 and LPP mRNA abundance in the femoral artery of wild type (WT) and zyxin 
knockout (Zyxko) mice from different age groups  
(A, B) Fold change in the expression of TRIP6 and LPP mRNA, respectively. Expression levels were normalized 
using the reference gene RPL32. The level of expression at 3 months of age in the femoral artery of WT and 
Zyxko animals was used as calibrator for the respective group (set to 1, indicated by the broken line). Each 
column represents the mean ± SEM of the indicated number of individual analyses. *p<0.05 as indicated 
4.1.2 TRIP6 and LPP protein levels in the femoral artery 
TRIP6 protein abundance continuously declined in both WT and Zyxko mice to a comparable degree 
over time (Figure 4.2 A, C). LPP protein levels also decreased with age in the femoral artery of both 
WT and Zyxko mice. However, only in Zyxko mice, this decline in LPP protein abundance between 6 
and 18 months of age was statistically significant (Figure 4.2 B, D). To rule out the possibility of a 
blotting variability, LPP protein from both WT and Zyxko mice of corresponding ages was further 
detected on the same blot. As expected, LPP protein levels remained similar in WT and Zyxko 
femoral arteries from 6 and 12 months old animals whereas this was significantly decreased in the 
18 months old Zyxko animals (Figure 4.3). 
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Figure 4.2 TRIP6 and LPP protein levels vary in an age-dependent manner in the femoral artery of 
Zyxko mice  
(A, B) Representative WB images for TRIP6 (A) and LPP (B) in WT and Zyxko femoral artery samples. (C, D)  shows 
quantification of the respective blots from (A) and (B). The individual values were normalized by using the 
loading controls, GAPDH and/or α-tubulin. The dashed line in (A) indicates an outlier value not included in the 
analysis. Each column represents the mean ± SEM of the indicated number of individual analyses. *p<0.05 as 
indicated 
 
Figure 4.3 LPP protein level significantly declines in the femoral artery of very old (18 months) 
Zyxko mice  
(A) Representative WB images for LPP, α-tubulin and GAPDH abundances in the femoral artery of 6, 12 and 18 
months old WT and Zyxko mice. (B) Statistical summary of the relative LPP protein level in the femoral artery of 
WT and Zyxko mice. The values were normalized by the loading controls, GAPDH and/or α-tubulin. Each column 
represents the mean ± SEM of the indicated number of individual analyses. *p<0.05 as indicated  
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4.2 Cellular distribution of TRIP6 and LPP protein in vascular smooth muscle cells  
4.2.1 Cellular localization of TRIP6 and LPP protein in mouse VSMCs 
TRIP6 protein was mainly localized in the cytosol (perinuclear space) and at cell-cell contacts rather 
than the nucleus (Figure 4.4 A). On the contrary, LPP protein follows the cellular distribution pattern 
of zyxin, i.e. it is mainly localized to focal adhesion as well as the nucleus in quiescent, i.e. non-
stretched VSMCs from the aorta of WT mice (Figure 4.4 B, C).   
 
Figure 4.4 Cellular localization of TRIP6 and LPP protein in VSMCs  
(A) TRIP6 immunofluorescence analysis, Scale bar, 20 µm. (B, C) LPP and zyxin co-localize in the focal adhesions 
(FA) but not in the nucleus (Nu). Scale bar, 20 µm (B).The plot profile over the yellow line shows maximum 
intensity of both zyxin (red) and LPP (green) at the FAs (C). Abbreviations: FA, focal adhesion; Nu, nucleus.  
4.2.2 Sub-cellular distribution of TRIP6 and LPP protein in response to stretch 
Under static conditions, little LPP or zyxin and no TRIP6 was present in the nucleus of VSMCs (Figure 
4.5 A, B, C). TRIP6 appeared largely unresponsive to stretching of the VSMCs for 8 and 24 hours, 
respectively (Figure 4.5 C). In contrast, LPP like zyxin translocated to the nucleus after 8 hours of 
stretching and maintained this level for a further 16 hours (Figure 4.5 A, B, D, E).   
Similar to zyxin, LPP mainly localized to the focal adhesions under static conditions but appeared to 
be absent from stress fibers (Figure 4.6 A) in the mouse VSMCs. In response to cyclic stretch, 
however, LPP like zyxin rapidly translocated to the stress fibers in the mouse VSMCs (Figure 4.6 B). 
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Figure 4.5 Nuclear translocation of zyxin, and LPP but not TRIP6 in response to cyclic stretch in 
mouse VSMCs  
(A, B, C) Representative WB images showing nuclear translocation of zyxin (A) and LPP (B) but not TRIP6 (C) after 
8 or 24 hours exposure to cyclic stretch (0-15% stretching at 0.5 Hz). (D) Relative change in LPP abundance in the 
cytosolic and nuclear fraction after exposure to cyclic stretch over time. Each column represents the mean ± SEM 
of n=3 experiments with individual VSMCs preparation. *p<0.05 as indicated 
 
Figure 4.6 Stretch-induced translocation of zyxin and LPP from focal adhesions to stress fibers in 
mouse VSMCs 
(A) Immunofluorescence images for zyxin and LPP in VSMCs under static conditions. (B) Immunofluorescence 
images showing the localization of zyxin and LPP after one hour exposure to cyclic stretch (0-15% at 0.5 Hz). 
Scale bar, 20 µm. The arrowheads mark stress fibers whereas focal adhesions are indicated by arrows. 
Abbreviations: FA, focal adhesion; SF, stress fiber; Nu, nucleus.  
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4.3 Regulation of VSMC phenotype by LPP and zyxin in vitro 
As the aforementioned clearly argued against a role of TRIP6 in VSMC mechanotransduction, the 
following experiments solely focused on LPP and zyxin. VSMCs were analyzed for their three 
hallmark properties, i.e. migration, proliferation, and contractile capacity both in 2-dimensional (2D) 
cell culture and 3-dimensional (3D) spheroid culture which more closely reflects the fundamental 
cellular interactions present in tissues119.  
4.3.1 Phenotype of VSMCs isolated from Lppko mice in 2D cell culture  
4.3.1.1 Lppko VSMCs migrate faster than WT VSMCs 
In the 2D or lateral sheath migration assay, the ability and speed by which cells close the gap or 
wound created by insertion of a silicon block was measured. In this setting, VSMCs isolated from 3-
months old Lppko mice showed  an approximately 2-fold greater speed of migration than their WT 
counterparts over a 24-hour period (Figure 4.7 A, B).  
 
 
Figure 4.7 2D or lateral sheath migration of WT and Lppko VSMCs 
(A) Distance of cell borders around an artificial gap (indicated by double arrow) in the beginning and 24 hours 
later in a monolayer composed of WT or Lppko VSMCs. (B) Quantitative measurement of the 2D-migration 
speed. Each column represents the mean ± SEM of n=5 individual VSMC preparation with at least 3 replicates. 
*p<0.05 as indicated  
4.3.1.2 Lppko VSMCs proliferate faster than WT VSMCs 
In 2D cell culture proliferation potential was analyzed by counting DAPI-stained nuclei immediately 
after and 72 hours post seeding. Compared to WT VSMCs, Lppko VSMCs showed higher numbers of 
DAPI-stained nuclei per optical field of view (Figure 4.8 A) at 72 hours. Approximately a 3-fold 
increase in cell number was observed in Lppko VSMCs as compared to 1.6-fold in WT VSMCs at this 
point (Figure 4.8 B).       
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Figure 4.8 2D proliferation analysis by counting DAPI stained nucleus per optical view  
(A) DAPI-stained nuclei at 0 and 72 hours post seeding from both WT and Lppko VSMC cultures. Scale bar 100 
µm. (B) Statistical summary to estimate the proliferation rate. Here, the data points represent the mean ± SEM 
of n=5 individual VSMC preparations with at least 30 images for each condition counted. *p<0.05 as indicated  
4.3.2 Phenotype of VSMCs isolated from Lppko and Zyxko mice in 3D cell culture  
To study the migration, proliferation and contractile capacity in 3D cell culture, spheroids was made 
with VSMCs isolated from the aorta of 3-months old animals. The spheroids were either seeded in 
collagen gel to study migration or fixed and paraffin embedded to study other properties. 
4.3.2.1 Zyxko and Lppko VSMC spheroids show higher invasion capacity than WT 
In contrast to WT, both Zyxko and Lppko VSMCs showed a significantly greater degree of sprouting 
in collagen gels. The cumulative distance travelled by all sprouts derived from a single spheroid was 
also significantly higher in Zyxko and Lppko VSMCs as compared to WT VSMCs (Figure 4.9 A-H).  
 
Figure 4.9 Spheroids composed of Zyxko or Lppko VSMCs reveal a higher invasion capacity in 
collagen gels than WT VSMCs  
(A, B, E and F) Representative images of 3D spheroids made from WT, Zyxko and Lppko VSMCs seeded into 
collagen gels. Scale bar 200 µm (C, G) Average number of sprouts originating from a WT or Zyxko spheroid (C) or 
Results  44 
 
from a WT or Lppko spheroid (G). (D, H) Comparison of the average cumulative sprout length between WT and 
Zyxko speroids (D) or WT and Lppko spheroids (H). Each column represents the  mean ± SEM of n=5 experiments 
with individual VSMC preparations and at least 15 spheroids analyzed per preparation. *p<0.05 as indicated 
4.3.2.2 VSMCs from Zyxko or Lppko mice showed significantly higher degree of 
proliferation in 3D spheroid culture than VSMCs from WT mice 
Of the paraffin embedded spheroids, 5 µm thick sections were prepared and stained for the 
proliferation marker Ki67 (Figure 4.10 A, C). Spheroids composed of WT VSMCs showed about 4% of 
cells proliferating whereas spheroids composed of Zyxko or Lppko VSMCs revealed an about 4-fold 
and 2-fold, respectively, increased number of Ki67-positive cells (Figure 4.10 B, D). 
 
 
Figure 4.10 VSMCs from Zyxko or Lppko mice seem to proliferate significantly faster than WT 
VSMCs in 3D spheroid culture  
(A, C) Immunofluorescence images of Ki67-positive VSMCs (red), nuclei counterstained with DAPI (blue), in 5-µm 
sections of spheroids composed of WT and Zyxko VSMCs (A) or WT and Lppko VSMCs (C). Scale bar 50 µm. (B, D) 
Statistical summary of the number of Ki67-positive VSMCs in WT or Zyxko spheroids (B) and WT or Lppko 
spheroids (D). Each column represents the mean ± SEM of n=5 individual spheroid preparations with at least 5 
spheroids per preparation analyzed. *p<0.05 as indicated 
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4.3.2.3 VSMCs isolated from Zyxko or Lppko mice rather seem to have a synthetic 
phenotype as compared to WT VSMCs in 3D spheroid culture 
To evaluate the contractile potential of VSMCs isolated from the aorta of 3-months old WT, Zyxko or 
Lppko mice in 3D culture, 5-µm sections of paraffin embedded spheroids were stained for α-smooth 
muscle actin (α-SMA) and calponin as contractile markers (Figure 4.11 A,B,C). Fluorescence intensity 
of the two marker proteins was normalized with DAPI stained nuclei number. Both Zyxko and Lppko 
VSMCs showed about 3 times lower expression of α-SMA in 3D culture as compared to WT VSMCs 
(Figure 4.11 D, E). Moreover, Lppko VSMCs revealed an approximately 6 times lower expression of 
calponin than WT VSMCs in this setting (Figure 4.11 F). 
 
 
Figure 4.11 VSMCs from Zyxko or Lppko mice express less markers for the contractile phenotype 
than WT VSMCs in 3D spheroid culture 
 (A, B) Immunofluorescence images of α-smooth muscle actin (α-SMA, red) positive VSMCs in WT or Zyxko 
spheroids (A) and WT or Lppko spheroids (B). (C) Immunofluorescence images of calponin (red) positive VSMCs 
in WT or Lppko spheroids. Nuclei were counterstained with DAPI (blue). Scale bar 50 µm. (D, E, F) Statistical 
summary of the relative fluorescence intensities for α-SMA (D, E) and calponin (F) in the different types of 
spheroids. Each column represents the mean ± SEM of n=5 individual spheroid preparations with at least 5 
spheroids per preparation analyzed. *p<0.05 as indicated 
4.3.3 Matrix metalloproteinase activity of VSMCs isolated from the aorta of WT, Zyxko 
and Lppko mice in vitro 
During vascular remodeling processes matrix metalloproteinase (MMP) activity increases to promote 
migration of vascular VSMCs32. Therefore, the relative level of MMP activity in WT, Zyxko and Lppko 
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VSMCs both in 2D and 3D cell culture was studied by determining fluorescence intensity of the DQ- 
gelatin substrate in the fixed VSMCs. 
4.3.3.1 Zyxko and Lppko VSMCs reveal higher matrix metalloproteinase activity in 2D cell 
culture than WT VSMCs 
Both Zyxko and Lppko VSMCs showed a markedly higher MMP activity as compared to WT VSMCs in 
2D cell culture (Figure 4.12). To find the possible contributor for this increased MMP activity, relative 
abundance of MMP9 and MMP2 was determined in addition by immunofluorescence analysis. In the 
cultured VSMCs, the majority of the detected MMP activity could be attributed to MMP9 (Figure 
4.12 D, E, F).  
 
 
Figure 4.12 Zyxko and Lppko VSMCs in 2D culture display higher MMP activity than WT VSMCs  
(A, B, C) Fluorescence intensity of DQ gelatin degradation (green), MMP2 (red) and nuclei (DAPI, blue) in 
methanol fixed VSMCs isolated from the aorta of 3-months old WT (A), Zyxko (B) or Lppko (C) mice. (D, E, F) 
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Fluorescence intensity of DQ gelatin (green), MMP9 (red) and  nuclei (DAPI, blue) in fixed WT (D), Zyxko (E) or 
Lppko (F) VSMCs. Scale bar 100 µm (images are representative for n=3 individual VSMC preparations). 
4.3.3.2 Significantly higher MMP activity also in VSMCs from Zyxko or Lppko mice in 3D 
cell culture as compared to VSMCs from WT mice  
Essentially the same experimental approach was taken as described before except that the isolated 
VSMCs were cultured as 3D spheroids which were fixed, cut into 5-µm thin sections and subjected to 
immunofluorescence analysis. Both Zyxko and Lppko spheroids revealed significantly higher 
(approximately 2-fold) MMP activity as compared to WT spheroids (Figure 4.13).  
 
 
Figure 4.13 Zyxko and Lppko VSMCs in 3D culture display significantly higher MMP activity than WT 
VSMCs  
(A, B) Gelatinase activity (green) and DAPI stained nuclei (blue) in sectioned spheroids composed of WT or Zyxko 
VSMCs (A) and WT or Lppko VSMCs (B). Scale bar 50 µm. (C, D) Statistical summary of the relative gelatinase 
activity detected in the aforementioned 3D cultured VSMCs. Each column represents the mean ± SEM, n=5 
independent VSMC preparations with at least 5 sectioned spheroids analyzed per preparation. *p<0.05 as 
indicated 
Immunofluorescence intensities for MMP9 and MMP2 were normalized on the basis of the DAPI 
stained nuclei per spheroid. In 3D cultured Lppko VSMCs namely MMP9 (10-fold increase, Figure 
4.14 A, C) but also MMP2 (2.5 fold increase, Figure 4.14 B, D) were significantly more abundant than 
in WT VSMCs. 
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Figure 4.14 Lppko VSMCs reveal a marked increase in MMP9 but also MMP2 expression as 
compared to WT VSMCs in 3D culture 
(A, B) Immunofluorescence images for MMP9 (A) and MMP2 (B) in sectioned (5 µm) spheroids made from WT or 
Lppko VSMCs. Scale bar, 50 µm. (C, D) Statistical summary of the difference in MMP9 (C) and MMP2 (D) 
abundance. Each column represents the mean ± SEM, of n=5 individual VSMC preparations with at least 5 
spheroids analyzed per preparation. *p<0.05 as indicated 
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4.4 Functional consequences of the loss of LPP in mice 
4.4.1 Young Lppko mice were smaller in size and had higher heart rate at resting 
conditions 
S129 mice with a global loss of LPP were reported to be devoid of any visible phenotype103. After 
backcrossing these mice onto a pure C57Bl6/J background, 3-months old homozygous Lppko mice 
presented with a smaller body weight (about 10%) than their WT littermates (Figure 4.15 A). 
Telemetry-based blood pressure (BP) monitoring did not reveal significant differences in systolic or 
diastolic BP between WT and Lppko mice at baseline (Figure 4.15 B, C). However, their heart rate at 
rest was significantly increased by about 10% as compared to WT mice, possibly due to their smaller 
size, while in the active state there was no such difference (Figure 4.15 D). High resolution 
ultrasound imaging revealed a further difference between Lppko mice and their WT littermates in 
that they presented with significantly lower early (E) and late (A) diastolic filling velocities but a 
slightly increased E/A ratio which was not significantly different though (Figure 4.15 E). 
 
Figure 4.15 Baseline phenotyping of young (3-months old) Lppko mice backcrossed onto the same 
C57Bl6/J background as the homozygous Zyxko mice  
Comparison between age-matched WT and Lppko mice in terms of body weight (A, n=15), systolic (B) and 
diastolic (C) blood pressure at rest, heart rate (D) in the resting state as compared to the active state (n≥5, 
*p<0.05 as indicated), and mean velocity for early (MVE) and late filling (MVA) of the left ventricle (E, n≥5, 
*p<0.05 vs. WT). 
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4.4.2 DOCA-salt treated young Lppko mice present with a greater blood pressure 
amplitude and a lower resistivity index as compared to age-matched WT mice  
To induce experimental hypertension, the DOCA-salt model was used as described before58. Due to a 
combination of central neurohumoral stimulation and an increased sodium and water retention by 
the kidneys this murine equivalent of human aldosterone causes a rather prominent increase in 
blood pressure that is maintained after 10 days on a stable plateau (Figure 4.16 A, B). In this study 
changes in blood pressure were recorded for 21 days post implantation of the DOCA pellet by radio 
telemetry. After 5 days of treatment, both WT and Lppko mice showed a significant rise in both 
systolic and diastolic blood pressure as compared to baseline. This rise in systolic BP was significantly 
higher in Lppko mice as compared to WT between days 11 and 15 (Figure 4.16 A), while there was 
no appreciable difference regarding the increase in diastolic BP over time (Figure 4.16 B). However, 
the resistivity index, recorded in the femoral artery by way of high resolution ultrasound imaging, 
which is an indirect measure of total peripheral resistance was significantly lower in the Lppko mice 
as compared to the age-matched WT mice at the end of treatment period (Figure 4.16 C). 
 
 
Figure 4.16 DOCA-salt treated Lppko mice reveal a greater blood pressure amplitude but a lower 
resistivity index as compared to age-matched WT animals   
(A, B) During DOCA-salt treatment, systolic blood pressure (A) but not diastolic blood pressure (B) hence blood 
pressure amplitude is transiently higher in Lppko mice as compared to age-matched WT mice (n≥5, *p<0.05 vs. 
WT mice). (C) Lppko mice also reveal a reduced resistivity index (measured in the femoral artery) as compared to 
WT animals at the end of the 21-day treatment period ((n≥5, *p<0.05 vs. WT mice). 
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4.4.3 VSMCs in the femoral artery of DOCA-salt treated young Lppko and WT mice show 
a comparable degree of proliferation and contractile marker gene expression  
Next, the femoral arteries of these animals were excised at the end of the treatment period and  
analyzed for the presence of proliferating VSMCs by staining sections of these arteries for 
proliferating cell nuclear antigen (PCNA). Both WT and Lppko VSMCs in the media revealed similar 
numbers of PCNA-positive nuclei (Figure 4.17 A, B). Also α-SMA (Figure 4.17 C, D) and calponin 
(Figure 4.17 E, F), markers for the contractile VSMC phenotype, did not differ in their abundance in 
the media of these arterial blood vessels, suggesting that in contrast to the isolated VSMCs the 
native VSMCs do not reveal a vascular phenotype neither at baseline nor following induction of 
experimental hypertension. 
 
Figure 4.17 No apparent phenotype difference between native WT and Lppko VSMCs following 21 
days treatment with DOCA-salt   
(A) Immunofluorescence images for PCNA (red) and DAPI (blue), and (B) statistical summary for n≥5 individual 
animals with 3 femoral artery sections analyzed per animal. Scale bar, 50 µm. (C) Immunofluorescence images 
for α-SMA (red), CD31 (green) and DAPI (blue), and (D) statistical summary for n≥5 individual animals with 3 
femoral artery sections analyzed per animal. Scale bar, 50 µm. (E) Immunofluorescence images for calponin 
(red), CD31 (green) and DAPI (blue), and statistical summary for n≥5 individual animals with 3 femoral artery 
sections analyzed per animal. Scale bar, 50 µm.  
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4.5 Evaluation of the potential of zyxin and LPP to functionally compensate for 
each other in VSMCs in vitro 
VSMCs isolated from the aorta of 3-months old Zyxko or Lppko mice similarly exhibited a synthetic 
phenotype in vitro whereas no apparent vascular phenotype could be detected in these animals in 
vivo. To evaluate whether LPP and zyxin can compensate for each other’s loss of function in the 
cultured VSMCs, LPP was transiently overexpressed in Zyxko VSMCs and zyxin vice versa in Lppko 
VSMCs. For this purpose, a plasmid only encoding GFP was used as a transfection control. After 
successful transfection of these expression constructs into the respective VSMCs, their migration 
properties both in 2D and 3D cell culture as well as their rate of proliferation in 2D culture was 
studied. 
4.5.1 Overexpression of Lpp in Zyxko VSMCs reverts their migration and proliferation 
behavior towards the level in WT VSMCs 
Transient overexpression of Lpp in Zyxko VSMCs significantly reduces their migration speed 
compared to that of untransfected Zyxko VSMCs. The migration rate of WT and Lpp-overexpressing 
Zyxko VSMCs was not significantly different (Figure 4.18 M). In addition Lpp-overexpressing Zyxko 
VSMCs showed significantly lower number of sprouts originating from 3D spheroids compared to 
that of untransfected Zyxko VSMCs (Figure 4.19 E). Cumulative sprout length was also significantly 
reduced in the Lpp-overexpressing Zyxko VSMCs. Both sprout number and cumulative sprout length 
were not significantly different in Lpp-overexpressing Zyxko and WT VSMCs (Figure 4.19 F).  
After Lpp overexpression, Zyxko VSMCs showed an approximately 2-fold increase in cell number 
after 72 hours, which was significantly lower than their untransfected control counterparts (3.5 
fold). Proliferation rate for WT and Lpp-overexpressing Zyxko VSMCs was not significantly different 
(Figure 4.18 N).  
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Figure 4.18 Transient overexpression of Lpp in Zyxko VSMCs reverts their migration and 
proliferation behavior towards the WT level in 2D cell culture 
(A, B, C) Immunofluorescence images for LPP (red) and GFP (green) in untransfected (A), control GFP transfected 
(B) and Lpp-transfected (C) Zyxko VSMCs. Scale bar 100 µm. (D) Representative WB images to check the level of 
overexpression. (E through L) Light microscopic images for the cell border at the beginning and 24 hours later in 
untransfected (E,F), control GFP transfected (G,H) and Lpp transfected Zyxko (I,J) and WT VSMCs (K,L). Scale bar 
100 µm. (M) Statistical summary for the migration speed observed in differently treated Zyxko and WT VSMCs. 
(N) Statistical summary for the relative fold changes in Zyxko and WT VSMCs number in the same experimental 
settings. Each column represents the mean ± SEM of n=3 experiments with individual VSMC preparations with at 
least 3 technical replicates. **p<0.01, *p<0.05 as indicated 
 
Figure 4.19 Overexpression of Lpp in Zyxko VSMCs reduces their migration rate towards the WT 
level in 3D spheroids seeded into collagen gel  
(A, B, C, D) Images of representative spheroids composed of untransfected (A), control GFP transfected (B), Lpp 
transfected (C) Zyxko VSMCs and WT VSMCs (D). Scale bar 100 µm. (E, F)  Statistical summary for the average 
number of sprouts (E) and  cumulative sprout length (F) originating from a single spheroid in that experimental 
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settings. Each column represents the mean ± SEM of n=3 experiments with individual VSMC preparations with at 
least 10 spheroids per condition. Abbreviation: ns, not significant. *p<0.05 as indicated  
4.5.2 Zyxin overexpression in Lppko VSMCs reduces their migration and proliferation 
behavior towards the level in WT VSMCs 
Compared to untransfected Lppko VSMCs, Zyx-overexpressing Lppko VSMCs migrated significantly 
slower in the 2D or lateral sheath migration assay. The migration rate of Zyx-overexpressing Lppko 
VSMCs was comparable to that of WT VSMSc (Figure 4.20 C, D). Zyx-overexpressing Lppko VSMC 
spheroids showed significantly lower numbers of sprouts (Figure 4.21 E) as well as a lower average 
cumulative sprout length (Figure 4.21 F) compared to that of untransfected Lppko VSMC spheroids. 
Both the sprout number and the cumulative sprout length were comparable in Zyx-overexpressing 
Lppko and WT VSMC spheroids (Figure 4.21 E, F).  
At the starting of the experiment (T0), the number of DAPI-stained nuclei was indifferent for 
differently transfected Lppko VSMCs and control WT VSMCs. However, after 72 hours, Zyx-
overexpressing Lppko VSMCs showed significantly lower number of DAPI-stained nuclei in contrast 
to untrasfected and GFP control transfected Lppko VSMCs. The number of nuclei was not different 
between the WT and Zyx-overexpressing Lppko VSMCs (Figure 4.20 E). 
 
 
Figure 4.20 Transient overexpression of Zyx in Lppko VSMCs rescues their synthetic phenotype 
towards the contractile phenotype in WT VSMCs  
(A) Immunofluorescence images for zyxin (red) and GFP (green) in untransfected, control GFP transfected and 
Zyx-overexpressing Lppko VSMCs. Scale bar 100 µm. (B) Representative WB images to check the level of 
overexpression. (C) Light microscopic images for the cell border at the beginning and 24 hours later in 2D cell 
culture. Scale bar 100 µm. (D) Statistical summary for the migration speed in the untransfected, control GFP 
transfected, and Zyx-overexpressing Lppko and WT VSMCs. (E) Statistical summary for the number of DAPI-
stained nuclei in the same experimental settings at the beginning (T0) and 72 hours later (T72). Each column 
represents the mean ± SEM of n=5 experiments with individual VSMC preparations with at least 3 technical 
replicates. Abbreviation: ns, not significant. ***p<0.001, **p<0.01, *p<0.05 as indicated 
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Figure 4.21 In 3D spheroid culture overexpression of Zyx in Lppko VSMCs reduces their migration 
rate towards the WT level  
(A, B, C, D) Images of representative spheroids seeded in collagen gel composed of untransfected (A), control 
GFP transfected (B), and Zyx transfected (C) Lppko VSMCs as well as non-transfected WT VSMCs (D). Scale bar 
100 µm. (E, F) Statistical summary for the average number of sprouts (E) and cumulative sprout length (F) 
originating from a single spheroid in the same experimental setting. Each column represents the mean ± SEM of 
n=3 experiments with individual VSMC preparations with at least 10 spheroids per condition. Abbreviation: ns, 
not significant. *p<0.05 as indicated  
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4.6 Both systolic and diastolic blood pressure are comparable in WT and Zyxko 
mice of different age 
Blood pressure was monitored in 3, 6 and 12 months old WT and Zyxko mice at baseline by using the 
CODA-noninvasive tail cuff system.  In Zyxko mice, systolic blood pressure was similar to that of WT 
animals in all age groups. Diastolic blood pressure was also not different among these genotypes 
(Figure 4.22). 
 
Figure 4.22 Comparable systolic and diastolic blood pressure at baseline in WT and Zyxko mice of 
different ages  
(A, B, C) Systolic and diastolic blood pressure in 3 months (A), 6 months (B) and 12 months (C) old WT and Zyxko 
mice. Each column represents the mean ± SEM of n =10 mice with 10 individual readings for each mouse.  
4.7 Cardiac systolic and diastolic parameters at baseline in WT and Zyxko mice at 
different ages 
Cardiac systolic functional parameters, i.e. cardiac output (CO), stroke volume (SV), ejection fraction 
(EF) and fractional shortening (FS) were measured from recorded echocardiographic images. All 
analyzed cardiac systolic parameters were similar in WT and Zyxko mice at 3, 6 and 12-months of 
age at baseline (Figure 4.23). Unlike cardiac systolic analysis, diastolic functional parameters were 
significantly different in Zyxko mice as compared to WT animals in all three age groups. Thus, both 
filling velocities of the left ventricle (early passive filling, E wave and active filling, A wave) during 
diastole were significantly lower in Zyxko mice as compared to WT mice at 3 and 6-months of age. 
Although the E wave was significantly lower, reduction of the A wave did not reach statistical 
significance at 12-months of age in the Zyxko mice (Figure 4.24).  
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Figure 4.23 Cardiac systolic functional parameters were comparable among WT and Zyxko mice 
from different age groups at baseline  
(A, B, C, D) Cardiac output (A), stroke volume (B), ejection fraction (C) and fractional shortening (D) in WT and 
Zyxko mice under basal conditions at 3, 6 and 12-months of age. The mean of each group is indicated by a 
horizontal line ± SEM of n ≥10 mice.  
 
Figure 4.24 Velocities for both early passive and late active filling of the left ventricle were 
markedly reduced  under basal conditions in Zyxko mice as compared to WT mice in all age groups  
(A, B) Left ventricular early passive (A) and late active (B) filling during diastole in unchallenged Zyxko and WT 
mice at 3, 6 and 12-months of age. (C) Ratio for the mitral valve E and A velocities at different ages of WT and 
Zyxko mice. The mean of each group is indicated by a horizontal line ± SEM of n ≥10 mice. ****p<0.0001, 
***p<0.001, *p<0.05 as indicated 
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4.8 The extent of the rise in blood pressure following angiotensin II treatment is 
comparable in WT and Zyxko mice 
To induce experimental hypertension, both WT and Zyxko mice were treated with angiotensin II 
(Ang II) at a dose of 1.5 mg/kg body weight/day via subcutaneous implantation of osmotic mini 
pumps (day 0). Blood pressure elevation was monitored on day 7 and just before terminating the 
experiment (day 15) by CODA-noninvasive tail cuff system. Elevations of both systolic and diastolic 
blood pressure were comparable in 3, 6 and 12-months old WT and Zyxko mice after 14 days 
treatment with Ang II (Figure 4.25). However, in Zyxko mice, the resulting rise in blood pressure 
appeared to be somewhat delayed as compared to WT mice, i.e. systolic blood pressure took 15 
days vs. 7 days to reach its maximum. Treatment of mice with 0.9% NaCl (vehicle control for Ang II) 
did not show any effect on blood pressure (by comparing vehicle control values in (Figure 4.25) to 
the basal values shown in (Figure 4.22)). 
 
Figure 4.25 Comparable level of blood pressure elevation in WT and Zyxko mice after angiotensin II 
treatment  
(A, B, C) Systolic blood pressure elevation after 7 and 14 days treatment with Ang II or vehicle in WT and Zyxko 
mice at 3 (A), 6 (B) and 12 (C) months of age. (D, E, F) Elevation in diastolic blood pressure in WT and Zyxko mice 
receiving the same treatments at 3 (D), 6 (E) and 12 (F) months of age. Each column represents the mean ± SEM 
of n = 5 mice per treatment condition. ***p<0.001, **p<0.01, *p<0.05 as indicated 
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4.9 Effect of Ang II treatment on cardiac systolic function of WT and Zyxko mice 
from different age 
4.9.1 Three months old Zyxko mice show comparable cardiac systolic functional 
parameters after Ang II treatment as age-matched WT mice  
Cardiac output (CO), ejection fraction (EF) and fractional shortening (FS) were similar in WT and 
Zyxko mice after 14 days of Ang II treatment compared to vehicle controls (Figure 4.26 A, C, D). 
However, stroke volume remained unchanged after treatment (Figure 4.26 B). Treatment of the 
mice with vehicle control, i.e. physiological saline, did not affect any of these parameters (by 
comparing vehicle control values (Figure 4.26) to the basal values shown in (Figure 4.24).     
 
Figure 4.26  Comparable cardiac systolic functional parameters after Ang II treatment in 3-months 
old WT and Zyxko mice  
(A-D) Cardiac output (A), stroke volume (B), ejection fraction (C) and fractional shortening (D) in WT and Zyxko 
mice after treatment with either Ang II or vehicle control for 14 days. The mean of each group is indicated by a 
horizontal line ± SEM of n ≥ 5 mice for each treatment.  
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4.9.2 Ang II treatment of 6-months old WT and Zyxko mice show comparable changes in 
the cardiac systolic functional parameters  
In 6-months old hypertensive WT and Zyxko mice, cardiac output (CO), stroke volume, ejection 
fraction and fractional shortening were reduced compared to their vehicle treated counterparts 
(Figure 4.27 A-D). Vehicle treatment did not have any effect on these parameters (when compared 
to situation at baseline). Ejection fraction and fractional shortening were significantly reduced only 
in Zyxko mice treated with Ang II but not in WT mice subjected to the same treatment regimen 
(Figure 4.27 C, D). However, none of the studied cardiac functional parameters were different 
among WT and Zyxko mice after Ang II treatment. 
 
Figure 4.27 Cardiac systolic functional parameters were also comparable in Ang II treated 6 months 
old WT and Zyxko mice  
(A-D) Cardiac output (A), stroke volume (B), ejection fraction (C) and fractional shortening (D) in 6-months old 
WT and Zyxko mice after treatment with either Ang II or vehicle control. The mean of each group is indicated by 
a horizontal line ± SEM of n ≥ 5 mice for each treatment. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 as 
indicated 
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4.9.3 12 months old Zyxko mice show significantly greater differences in cardiac systolic 
function than WT mice after Ang II treatment  
Cardiac output (CO), stroke volume (SV) and ejection fraction (EF) were significantly reduced in Ang 
II treated Zyxko mice when compared to their vehicle treated counterparts (Figure 4.28 A-C).  After 
Ang II treatment, Zyxko mice showed significantly greater reductions in CO, SV and EF as compared 
to WT mice. However, the reduction in fractional shortening (FS) after Ang II treatment was 
statistically insignificant between WT and Zyxko mice (Figure 4.28 D). 
 
Figure 4.28 Cardiac systolic function was significantly different in Ang II treated WT and Zyxko mice 
at 12-months of age  
(A-D) Cardiac output (A), stroke volume (B), ejection fraction (C) and fractional shortening (D) in 12-months old 
WT and Zyxko mice after 14 days of treatment with either Ang II or vehicle control. The mean of each group is 
indicated by a horizontal line ± SEM of n ≥ 5 mice for each treatment. ****p<0.0001, **p<0.01, *p<0.05 as 
indicated 
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4.10 Cardiac diastolic functional parameters were similar after Ang II treatment in 
WT and Zyxko mice of different age 
Like under basal conditions, velocities for both the passive filling (E wave) and active filling (A wave) 
of the left ventricle were significantly lower in vehicle treated Zyxko mice as compared to those of 
WT at 3 (Figure 4.29), 6 (Figure 4.30) and 12 (Figure 4.31) months of age. After Ang II treatment, 
both velocities were significantly lower only in WT mice as compared to their vehicle control treated 
counterparts in all age groups. Like the E/A  ratio, velocities for both early passive and late active 
filling were not significantly different in WT and Zyxko mice after Ang II treatment in all age groups.   
 
Figure 4.29 Diastolic filling velocities were comparable in Ang II treated WT and Zyxko mice at 3-
months of age  
(A, B) Velocities for early filling MVE wave (A) and late filling MVA wave (B) in either vehicle or Ang II treated WT 
and Zyxko mice. (C) Ratio for E and A wave in the same experimental setting. The mean of each group is 
indicated by a horizontal line ± SEM of n ≥ 5 mice for each treatment. ****p<0.0001, **p<0.01 as indicated 
 
Figure 4.30 Cardiac diastolic functional parameters were not different in Ang II treated WT and 
Zyxko mice at 6-months of age  
(A, B) Early passive, MVE (A) and late active filling, MVA (B) in 6-months old WT and Zyxko mice after 14 days of 
treatment with either Ang II or its vehicle control. (C) Ratio for E and A wave in the same experimental setting. 
The mean of each group is indicated by a horizontal line ± SEM of n ≥ 5 mice for each treatment. ***p<0.001, 
**p<0.01 as indicated 




Figure 4.31 Ang II treated Zyxko and WT mice show comparable cardiac diastolic functional 
parameters at 12-months of age  
(A, B) Early passive filling, MVE (A) and late active filling, MVA (B) after 14 days of treatment with either Ang II or 
vehicle in 12-months old WT and Zyxko mice. (C) Ratio for E and A wave in the same experimental setting. The 
mean of each group is indicated by a horizontal line ± SEM of n ≥ 5 mice for each treatment. ***p<0.001, 
**p<0.01, *p<0.05 as indicated  
4.11 Angiotensin II treatment induces significant heart hypertrophy only in WT 
mice  
To evaluate the level of heart hypertrophy in WT or Zyxko mice induced by systemic Ang II 
treatment, left ventricular mass was calculated from the recorded echocardiographic images and 
normalized with body weight. Only the WT mice showed a significant degree of hypertrophy after 
Ang II as compared to  vehicle control treatment at 3, 6 and 12-months of age (Figure 4.32 A-C). The 
ratio between heart weight and body weight was also calculated to better evaluate the hypertrophic 
response of the heart. Ang II treated WT mice showed a significantly higher ratio when compared to 
vehicle control treated WT animals at 3, 6 and 12-months of age (Figure 4.32 D-E). Judged by this 
classical parameter, Zyxko mice showed significant induction of hypertrophy at 3 and 6-months of 
age which, however, was weaker as compared to 3 months old WT mice subjected to the same 
treatment regimen (Figure 4.32 D-E).   
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Figure 4.32 Angiotensin II treatment induces significant hypertrophy of the heart primarily in WT 
mice of different ages  
(A, B, C) Normalized left ventricular mass (echocardiography parameter) of vehicle and Ang II treated WT and 
Zyxko mice at 3 (A), 6 (B) and 12 (C) months of age. (D, E, F) Ratio of heart weight to body weight for vehicle and 
Ang II treated WT and Zyxko mice at 3 (D), 6 (E) and 12 (F) months of age. The mean of each group is indicated by 
a horizontal line ± SEM of n ≥ 5 mice for each treatment. ***p<0.001, **p<0.01, *p<0.05 as indicated 
4.12 Angiotensin II treatment induces higher expression of CTGF and LOX in the 
heart of Zyxko mice from different age 
As the Ang II treated and thus hypertensive Zyxko mice exhibited signs of systolic dysfunction but 
only modest cardiac hypertrophy, next their tendency to develop cardiac fibrosis was evaluated by 
analyzing the expression of connective tissue growth factor (CTGF) and lysyl oxidase (LOX), one of 
the major collagen cross linking enzymes. In fact, cardiac tissue of Zyxko mice revealed significantly 
higher levels of both gene products after Ang II treatment at 3, 6 and 12-months of age (Figure 4.33). 
Cardiac tissue from vehicle treated 6 or 12 months old Zyxko mice showed markedly increased levels 
of CTGF and LOX mRNA when compared to their WT counterparts. Strikingly, 14 days treatment with 
Ang II induced expression of these genes in the heart of age-matched WT mice only to a level that is 
comparable to that of the vehicle control treated Zyxko vehicle control mice. 
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Figure 4.33 Angiotensin II treatment induces higher expression of CTGF and LOX in the heart of 
Zyxko mice as compared to WT mice irrespective of their age  
(A, B, C) Relative mRNA abundance of CTGF in cardiac tissue derived from 3 (A), 6 (B) and 12 (C) months old WT 
and Zyxko mice after 14 days of treatment with either Ang II or vehicle control. (D, E, F) Relative mRNA level of 
LOX at same experimental conditions. Relative mRNA abundance was normalized using that of the reference 
gene RPL32. The level of mRNA in the cardiac tissue of vehicle control treated WT mice was used as a calibrator 
for the different age groups (set to 1, indicated by the broken line). Each column represents the mean ± SEM of n 
≥ 5 mice for each condition. ***p<0.001, **p<0.01, *p<0.05 as indicated 
4.13 Angiotensin II treated Zyxko mice show significantly more pronounced cardiac 
fibrosis in all age groups 
The degree of cardiac fibrosis was determined by staining for collagen in the hearts of WT and Zyxko 
mice after 14 days of Ang II treatment. Collagen fibers were visualized by Masson trichrome and van 
Gieson’s staining protocols. Both protocols revealed significantly higher collagen fiber deposition in 
the hearts of Ang II treated Zyxko mice as compared to Ang II treated WT mice. After Ang II 
treatment, perivascular collagen deposition was observed both in WT and Zyxko mouse hearts, 
whereas interstitial collagen deposition only occurred in the hearts of the Zyxko mice at the age of 3-
months (Figure 4.34 A,B), 6-months (Figure 4.35 A,B) and 12-months (Figure 4.36 A,B). To analyze 
the magnitude of this collagen deposition, numbers of collagen-rich spots were counted under the 
microscope in a blinded  fashion. This way, Ang II treated WT mice get a score for fibrotic collagen 
deposition of around 1, representing solely perivascular collagen staining, which was similarly found 
in the vehicle treated WT and Zyxko mice. After Ang II treatment, Zyxko mouse hearts showed 
significantly higher fibrotic collagen deposition scores in all age groups as compared to WT mice 
subjected to the same treatment regimen (Figure 4.34 C); (Figure 4.35 C); (Figure 4.36 C). Finally, to 
avoid any subjective measurement bias, the area of collagen deposition from the captured 
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microscopic images was quantified by using an image analysis macro in a blinded fashion. Again, only 
in the hearts of Zyxko mice the fibrotic area was significantly enlarged following Ang II treatment as 
compared to their vehicle treated counterparts or to WT mice subjected to Ang II treatment in all 
age groups (Figure 4.34 D); (Figure 4.35 D); (Figure 4.36 D).   
 
Figure 4.34 Higher cardiac fibrosis is observed in angiotensin II treated Zyxko mice at 3-months of 
age  
(A, B) Masson trichrome (A, red: cardiomyocytes, blue: fibrosis) and van Gieson (B, yellow: cardiomyocytes, pink: 
fibrosis) staining for collagen fiber deposition in cardiac tissue sections of WT and Zyxko mice subjected to 
systemic vehicle or Ang II treatment at 3-months of age. Scale bar 200 µm. (C, D) Summarized fibrotic score (C) 
and area of collagen deposition (D). Each column represents the mean ± SEM of n ≥ 5 mice for each condition 
with 3 sections for fibrotic score and at least 10 captured images for fibrotic area analyzed per animal. 
***p<0.001, *p<0.05 as indicated 
 
Figure 4.35 Prominent cardiac fibrosis is observed in angiotensin II treated Zyxko mice at 6-months 
of age  
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(A, B) Masson trichrome (A, red: cardiomyocytes, blue: fibrosis) and van Gieson (B, yellow: cardiomyocytes, pink: 
fibrosis) staining for collagen fiber deposition in cardiac tissue sections of WT and Zyxko mice subjected to 
systemic vehicle or Ang II treatment at 6-months of age. Scale bar 200 µm. (C, D) Summarized fibrotic score (C) 
and area of collagen deposition (D). Each column represents the mean ± SEM of n ≥ 5 mice for each condition 
with 3 sections for fibrotic score and at least 10 captured images for fibrotic area analyzed per animal. 
***p<0.001, *p<0.05 as indicated 
 
Figure 4.36 Even more prominent cardiac fibrosis is observed in angiotensin II treated Zyxko mice at 
12-months of age 
(A, B) Masson trichrome (A, red: cardiomyocytes, blue: fibrosis) and van Gieson (B, yellow: cardiomyocytes, pink: 
fibrosis) staining for collagen fiber deposition in cardiac tissue sections of WT and Zyxko mice subjected to 
systemic vehicle or Ang II treatment at 12-months of age. Scale bar 200 µm. (C, D) Summarized fibrotic score (C) 
and area of collagen deposition (D). Each column represents the mean ± SEM of n ≥ 5 mice for each condition 
with 3 sections for fibrotic score and at least 10 captured images for fibrotic area analyzed per animal. 
***p<0.001, *p<0.05 as indicated 
4.14 Ang II treated Zyxko mice age-independently show significantly higher levels 
of lysyl oxidase in the heart than WT mice 
Immunofluorescence staining was performed to quantify the level of lysyl oxidase (LOX) in the 
cardiac tissue sections derived from WT or Zyxko mice at the different ages. After Ang II treatment at 
3 and 6 months of age, both WT and Zyxko mouse hearts showed significantly higher levels of LOX 
compared to those of the respective vehicle controls. Nevertheless, LOX abundance in Ang II treated 
Zyxko mouse hearts was significantly higher compared to that of WT mouse hearts at 3 and 6-
months of age (Figure 4.37 A-C). At 12-months of age, only Zyxko mice showed a significant increase  
in LOX protein abundance in the heart in Ang II treated animals over vehicle control treated animals 
as well as Ang II treated WT mice (Figure 4.37 A, D).  
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Figure 4.37 Lysyl oxidase level is significantly higher in Ang II treated Zyxko mouse hearts 
independently of the age of the animals 
(A) Immunofluorescence images for lysyl oxidase (LOX) in the cardiac tissue sections of differently treated 3, 6 
and 12-month old WT and Zyxko mice. Scale bar 100 µm. (B, C, D) Statistical summary for the LOX-specific 
fluorescence intensity in 3 (B), 6 (C), and 12 (D) months old animals. Each column represents the mean ± SEM of 
n ≥ 5 mice for each condition with at least 3 sections analyzed per animal. ***p<0.001, **p<0.01, *p<0.05 as 
indicated 
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4.15 Adult cardiac fibroblasts isolated from 3-months old Zyxko mice show 
significantly higher levels of pro-fibrotic gene expression after TGF-1 
treatment 
To investigate the source of the prominent cardiac fibrosis in the heart of Zyxko mice, cardiac 
fibroblasts isolated from 3 months old WT or Zyxko mice were treated with the pro-fibrotic stimulus 
TGF-1. Interestingly, Zyxko cardiac fibroblasts showed a markedly higher expression of CTGF, 
collagen 1 and lysyl oxidase (LOX) already at baseline when compared to TGF-1 stimulated WT 
cardiac fibroblasts. For collagen 3 and integrin-1, this effect was also clearly visible but did not 
reach statistical significance. Treatment of the Zyxko cardiac fibroblasts with TGF-1 approximately 
doubled the expression of all gene products except integrin-1, which did not seem to be sensitive 
to TGF-1 in these cells. Figure 4.38 summarizes the aforementioned findings.   
 
Figure 4.38 Adult cardiac fibroblasts from Zyxko mice showed significantly higher expression of pro-
fibrotic genes than cardiac fibroblasts from WT mice 
(A-E) Relative expression levels of CTGF (A), Col I (B) LOX (C), Col III (D) and integrin 1 mRNA (E) at baseline and 
following stimulation with TGF-1 (10 ng/ml) for 24 hours in adult cardiac fibroblasts isolated from 3 months old 
WT or Zyxko mice. Expression levels were normalized using the reference gene RPL32. The level of expression in 
the WT cardiac fibroblasts was used as a calibrator (set to 1, indicated by the broken line). Each column 
represents the mean ± SEM of n = 5 experiments with individual adult cardiac fibroblast preparations. 
***p<0.001, **p<0.01 as indicated 
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5 Discussion 
Hypertension (high blood pressure) is responsible for about 13% of total deaths worldwide and 
reported to correlate significantly with the risks for, e.g. coronary heart disease, stroke or chronic 
renal failure. From the clinical standpoint, hypertension is an enigma. It is devoid of any obvious 
early signs but develops insidiously. Blood pressure (mean arterial pressure) is regulated by cardiac 
output and total peripheral resistance which is intricately linked to contraction of the medial VSMCs 
within the vessel wall of the small arteries and arterioles. Together with sympathetic activity, cardiac 
output is increased at the early stages of hypertension development but normalized once blood 
pressure has been established at the elevated level. Total peripheral resistance behaves differently 
and is the physical reason for the persistent (further) rise of blood pressure25. Augmented peripheral 
resistance is inferred to the narrowing of the aforementioned resistance-sized small arteries and 
arterioles that ensues as part of the (mal)adaptive (cardio)vascular remodelling process to normalize 
wall stress in the wall of these blood vessels. Vascular smooth muscle cells as well as cardiomyocytes 
and cardiac fibroblasts elicit functional changes to cope with this local environmental shift by 
converting the mechanical stimulus to cellular events like alterations in gene expression or even 
phenotypic shifts. However, the mechanisms underlying mechanotransduction in these cells are not 
particularly well understood and investigated so far. In the present study, efforts have been made to 
better understand cytoskeletal proteins associated with focal adhesions (FA) such as zyxin and LPP, 
their role in mechanotransduction and the control of such cardiovascular remodelling process in 
response to pathophysiological stress.  
5.1 The level of LPP level decreases in arterial blood vessels of aging Zyxko mice 
to unveil its function as a stabilizer of the VSMC phenotype  
A zyxin orthologous cytoskeletal protein has been shown to be required for the viability of 
drosophila, whereas in C. elegans this orthologous protein is involved in dystrophin-dependent 
muscle degeneration120,121. In contrast, Zyxko mice lack any noticeable abnormalities under basal 
conditions110. Also Lppko mice seem to be free from any definitive phenotype apart from some 
possible embryonic lethality which might affect the female offspring103. In zebrafish, however, Lpp is 
required for proper embryonic development100. A possible explanation for this paradox in mice 
might be the presence of a functional redundancy between individual members of the zyxin family 
of LIM-domain containing proteins. The presumption of a compensatory mechanism(s) in mice is 
further corroborated by the fact that zyxin and its closest homologues LPP and TRIP6 are 
represented by a single orthologous gene product, Zyx102 in Drosophila melanogaster and ZYX-1 in 
Discussion  71 
 
C. elegans121,122. Therefore, in simpler organisms, the loss of this LIM-domain containing protein 
cannot be compensated and thus has detrimental effects on vital functions. In higher organisms, this 
effect presumably is lost with the evolutionary emergence of multiple family members with 
redundant functional roles that can likely replace each other. Moreover, zyxin, LPP and TRIP6 share 
some interaction partners, which apart from their similar protein structure, is an extra indication 
that these proteins share one or more functions. 
Zyxin has been shown to be involved in regulating the expression of mechanosensitive genes both in 
endothelial cells and VSMCs55–58. It also plays a prominent role in determining the phenotype of 
VSMCs in vitro58. It was therefore quite unexpected that adult Zyxko mice revealed such a vascular 
phenotype (shift from contractile to synthetic) when subjected to an experimental hypertension 
model only in very old, i.e. 18 months old animals111. By considering this unusual age-dependency, 
we hypothesized that a possible compensatory mechanism might hinder the younger adult Zyxko 
mice, precisely the VSMCs within the wall of the arterial blood vessels, to force them into an 
hypertension induced vascular remodelling process. In this compensatory event, perhaps the two 
most closely related zyxin homologs LPP and/or TRIP6 conceal the effects of the zyxin deficiency. 
This notion was tested through analysing their age-dependent abundance in arterial blood vessels of 
Zyxko mice. Unlike in wild type animals, both LPP and TRIP6 mRNA abundance declined with age in 
the Zyxko mice but only LPP protein levels significantly dropped by about 50% in the very old Zyxko 
mice. Further evidence that LPP rather than TRIP6 can compensate for the loss of zyxin in the arterial 
VSMCs was derived from the very different subcellular distribution of both proteins in these cells at 
baseline and following exposure to cyclic stretch. In fact, LPP essentially matched the intracellular 
localisation and stretch-induced redistribution to the nucleus and to the stress fibers of zyxin in a 
head to head comparison in VSMCs isolated from adult wild type mice. In contrast, TRIP6 only poorly 
associated with focal adhesions and proved to be essentially insensitive to cyclic stretch. In the 
present study, the antibody that was used to detect TRIP6 was raised against a peptide positioned 
close to the N-terminus of TRIP6110, which is missing in a shorter, strictly nuclear isoform identified at 
least in humans79. Whether such an isoform also exists in mice is yet to be determined. Hence, our 
analyses did not provide any evidence that full-length TRIP6, like zyxin or LPP, could translocate to 
the nuclei of murine WT VSMCs upon stretch.  
Structurally, LPP is the closest homolog of zyxin while TRIP6 lacks not only the  α-actinin but also 
VASP-binding motif in the pre-LIM region that both LPP and zyxin have91. Stretching of VSMCs 
isolated from VASP knockout mice in fact failed to induce translocation of zyxin to stress fibers or to 
the nucleus, and failed to control expression of  prototypic mechanosensitive genes in these cells 
(unpublished observation, doctoral thesis of I. Eberhard 2004, University of Goettingen). When 
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combined these observations suggest that TRIP6, probably because of its lack of interaction with α-
actinin and/or VASP, is incapable of transducing mechanical signals perceived by the focal adhesions 
and transmitted via the actin cytoskeleton to the nuclei of VSMCs. Due to the presence of the 
corresponding binding motifs (Figure 5.1) as well as its expression profile, on the other hand, LPP 
looks like the candidate to maintain the quiescent differentiated VSMC phenotype in Zyxko mice up 
to 12 months of age.  
 
Figure 5.1 Molecular interaction network between mouse Zyxin, LPP and VASP 
This protein-protein interaction network was made using the web-based tool STRING (version 10.5, accessed on 
14.05.2017). Pink lines denote experimentally determined interactions while the green lines denote interactions 
based on text mining. Abbreviations: Nos1ap, nitric oxide synthase-1; Fscn1, Fascin Actin-Bundling Protein-1; 
Abl1, Abelson murine leukemia viral oncogenic homologue-1; Jub, ajuba; Wtip, Wilms tumor-1 
interacting protein; Lasp1, LIM and SH3 protein-1; Cnn2, calponin-2; Enah, enabled homolog; Vasp, vasodilator 
stimulated phosphoprotein.   
5.2 VSMCs isolated from adult Lppko mice reveal a synthetic phenotype while the 
young (3-months old) animals appear to be protected from  hypertension-
induced arterial remodeling  
In adult arterial blood vessels, VSMCs are essentially committed to carry out their contractile 
function while exhibiting an extremely low rate of proliferation, migration and synthesis of 
extracellular matrix (ECM) components at the same time. These mature differentiated VSMCs also 
show extensive phenotypic plasticity under physiological and pathophysiological conditions to confer 
a survival advantage in higher organisms123. Excessive wall stress during hypertension causes 
switching of their phenotype from this quiescent, contractile state to a proliferative and synthetic 
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state mainly to normalise any prolonged rise in wall stress25. Interestingly, arterial VSMCs isolated 
from 3 months old Lppko mice mimic the synthetic phenotype of VSMCs isolated from age-matched 
Zyxko mice58 with somewhat less pronounced but nonetheless strikingly similar pro-migratory, 
hyper-proliferative, and poorly contractile characteristics both in 2-dimensional (2D) and 3-
dimensional (3D) cell cultures. VSMCs cultured in a 2D environment often behave differently from 
cells cultured in a 3D matrix in which they are normally embedded in the vessel wall119.  
Moreover, In pathological settings like hypertension, the prolonged rise in wall stress leads to 
enhanced ECM turnover by humoral factors, thereby triggering VSMC hypertrophy (in conduit 
arteries) or VSMC hyperplasia (in arterioles) to reinforce the vessel wall4. Matrix metalloproteinase 
(MMP) activity is increased during such vascular remodeling processes for breaching the ECM to 
support the migration of VSMCs32. In fact, VSMCs isolated from both Zyxko and Lppko mice revealed 
significantly higher MMP activity as compared to that of VSMCs isolated from WT mice both in 2D 
and in 3D cell cultures. This increased MMP activity was largely attributable to MMP9 rather than 
MMP2, and this finding correlated well with the higher rate of migration of the VSMCs isolated from 
Zyxko or Lppko mice while VSMCs isolated from Mmp9ko mice display both impaired migration and 
proliferation33.  
Since its discovery as a translocation partner in a variety of human cancers, the function of LPP has 
been studied mainly in the context of cancer development and progression124. However, the 
physiological role of LPP or its significance in other pathological situations, e.g. hypertension, 
remained elusive so far. In the literature, LPP is mainly referred to as a protooncogene which 
promotes cancer development by aberrant nuclear translocation together translocation partners like 
the HMGA2 or MML genes101,102,125,126. In contrast, LPP has previously been described as a positive  
regulator for cellular migration in VSMC98, in mouse embryonic fibroblasts103 as well as in lung 
metastasized breast cancer cells101,102. Moreover, LPP has been reported to prevent the migration 
and tissue invasion of human lung adenocarcinoma cells125. The conflicting reports about the role of 
LPP in cellular migration might be context-dependent or due to heterogeneity of the studied models. 
This discrepancy could further be explained by the methods employed for knocking down LPP, e.g. 
by RNA interference. 
Thus, fibroblasts isolated from E14.5 Lppko embryos, on a S129 background though, displayed 
impaired migration and proliferation103. In  the present study with homozygous adult Lppko mice on 
a pure C57BL/6J background from which arterial VSMCs were isolated, we noted that these cells in 
culture clearly present with a synthetic phenotype, i.e. Increased proliferation and migration rates. 
One reason for such inconsistency could be differences between cell types as well as in terms of 
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development temporally different roles of LPP. On top of that, choices of method and readout to 
analyze such functional properties could also be an important source of disagreement. 
Conventionally, in the 2D migration assay, frequently referred to as scratch-wound assay, closure of 
the gap is measured rather than counting the number of migrating cells127. In their study, Vervenne 
et al.103 have generated the wound by scraping away parts of the cell monolayer which may have 
given rise to possible artifacts due to variable wound size and/or mechanical cell damage (triggering 
inflammation)128. In addition, instead of measuring the gap closure over time by the migrating cell 
front, they have counted the number of cells migrating to the wounded area. In this study, silicon 
blocks were used to create nearly identical gaps without any mechanical damage to the cells and 
measured the distance between the migrating fronts of cells, i.e. gap closure. Moreover, we have 
also analyzed the 3D invasion capacity of the Lppko VSMCs in the form of a sprouting assay with 
VSMCs cast as spheroids into collagen gels. To assess their rate of proliferation, we have counted 
absolute cell numbers over time as well as labeled the proliferating cell with a definitive marker of 
proliferation, i.e. Ki67, whereas Vervenne et al.103 have used metabolism-based assay. Furthermore, 
several lines of evidences have established LPP as a novel marker for the differentiated VSMC 
phenotype98,129. Hence, in the VSMCs isolated from the Lppko mice, lower expression of contractile 
proteins together with more migration and proliferation did not come as a surprise, but instead 
reflected their presumed shift towards the synthetic phenotype. Evaluation of the contractile 
capacity of resistance arteries isolated from these animals would provide additional and solid 
evidence for our assumption but has not been carried out yet. 
Ubiquitous Lppko mice on a pure C57BL/6J background are exclusively raised in our animal facility; 
they therefore needed to be phenotyped with regard to their cardiovascular status. Young Lppko 
mice (3-months old) are somewhat smaller in size than their wild type counterparts. Under basal 
conditions, they do not show any discernible differences in systolic or diastolic blood pressure but 
present with a significantly higher heart rate at rest that might be associated with their smaller 
size130. Although they have a normal cardiac  function in systole at rest, they present with  
significantly lower diastolic filling velocities of the left ventricle that may indicate an impaired cardiac 
function in diastole131. Although assessment of diastolic dysfunction ideally requires invasive 
measurements (cardiac catheterization), the left ventricular filling velocities in diastole serve as a 
non-invasive surrogate parameter with controversial specificity132,133. Filling of the left ventricle 
during diastole is predominantly regulated by the interaction of left atrial compliance and the rate of 
left ventricular relaxation. The transmitral E wave depends on active left ventricular relaxation, 
hence a slow or prolonged left ventricular relaxation causes a decrease in E velocity. Although the 
functional significance of an impaired relaxation of the left ventricle for its refilling is not fully 
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understood131, it becomes apparent at an early stage of left ventricular dysfunction which could lead 
to adverse cardiovascular events134.   
DOCA, the murine equivalent of aldosterone, is used to increase blood pressure inter alia by 
retention of sodium and water in the kidneys but also by reinforcing central blood pressure 
control117. There are two variants of this experimental hypertension model: one is the renovascular 
two kidney model whereas the other is the one kidney/one clip model which induces quite a strong 
increase in blood pressure. In this study, the two kidney model with administration of DOCA and salt 
loading has been used for maximum animal survival. After induction of experimental hypertension, 
systolic blood pressure elevation was somewhat higher in the young Lppko mice as compared to 
their wild type counterparts while diastolic blood pressure elevation was not significantly different. 
Blood pressure changes in Zyxko mice at this age following DOCA-salt treatment still need to be 
analyzed but in 6 months old animals no such differences could be observed111.  
The significantly lower resistivity index (RI) in the femoral artery of the Lppko mice, an indirect 
measure of total peripheral resistance, may indicate an ensuing contraction deficit of the medial 
VSMCs of the small arteries and arterioles but was not yet reflected by a parallel lower response of 
diastolic blood pressure to the DOCA-salt treatment regimen. The vascular resistivity  and pulsatility 
indices are calculated from the blood flow velocities during the cardiac cycle to estimate the 
resistance in arteries. Originally, both indices were introduced to detect peripheral vascular 
diseases135–137. Thus, the relatively reduced change in the resistivity index of the Lppko mice in 
response to experimental hypertension can be interpreted as indicative for a lower total peripheral 
vascular resistance in these mice. In this context, it is worth mentioning though that the resistivity 
index does not solely depend on vascular resistance but also is regulated by vascular compliance 
which varies from individual to individual138. Moreover, the medial VSMCs in the femoral arteries of 
the hypertensive Lppko mice were not different from those of age-matched wild type animals with  
respect to proliferation index or the presence of markers of the contractile phenotype. Nonetheless, 
these first signs of the presence of an altered vascular remodeling in these animals suggest that the 
arterial VSMCs may switch to the synthetic phenotype much faster than in Zyxko mice, where such a 
vascular phenotype manifests itself only at 18 months of age111. In any case, much older Lppko mice 
(6, 12 and 18 months old) need and will be analyzed in the near future in this model. Conversely, the 
fact that the synthetic phenotype of the arterial VSMCs isolated from 3 months old Lppko mice does 
not reveal itself in form of a vascular phenotype in these animals argues for a compensatory role of 
zyxin that may be overcome only by analyzing Lpp/Zyx double-knockout mice that are currently 
being generated.  
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5.3 Overexpression of either zyxin or LPP in their reciprocal knockout VSMCs fully 
compensates for their loss of function  
VSMCs isolated from age-matched young Zyxko or Lppko mice both revealed synthetic phenotypes 
in vitro. Overexpression of LPP in Zyxko VSMCs and vice versa of zyxin in Lppko VSMCs normalized 
their pro-migratory phenotype in both 2D and 3D cell culture systems, and reversed their increased 
rates of proliferation towards basal levels. So that these findings strongly argue for the presumed 
functional redundancy among these two LIM-domain containing members of the zyxin family (Figure 
5.2). Although changes in zyxin abundance in 3, 6, 12 and 18 months old Lppko mice still need to be 
analyzed, we would assume that zyxin does compensate for the loss of LPP in these animals up to a 
certain age (presumably sooner than in Zyxko mice) where the vascular loss of function phenotype 
unmasks itself. However, to ultimately proof this functional redundancy, analyses (basal conditions 
and hypertension) of Lpp/Zyx double-knockout are required; these will commence in due course. 
Until now, our findings suggest an important protective role for both zyxin family members in  
hypertension-induced arterial remodeling that may have therapeutic implications. 
 
Figure 5.2 Schematic representation of the possible functional redundancy among LPP and zyxin to 
maintain a quiescent contractile phenotype in arterial VSMCs 
Possible interacting fronts are denoted in green squares with white borders: 1. Like zyxin, LPP can regulate the 
expression of genes to determine the VSMCs phenotype via RhoA- MRTFA signaling pathway similar to zyxin; 2. 
LPP can also take part in the generation and maintenance of stress fibers in response to stretching. Based on58.  
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5.4 Loss of zyxin shifts the balance to a more pro-fibrotic milieu in the heart 
Very much like VSMCs in large conduit arteries, terminally differentiated cardiomyocytes respond to 
arterial hypertension by hypertrophy to neutralize the wall stress13. Following compensatory 
cardiomyocytes hypertrophy, cardiac dysfunction develops due to enhanced loss of cardiomyocytes 
and increased deposition of extracellular matrix (ECM) proteins by cardiac fibroblasts14–16. Zyxin has 
been reported to protect cardiomyocytes from apoptosis139. In a model of experimental 
hypertension (DOCA-salt treatment), 12 months old Zyxko mice presented with both systolic 
dysfunction in vivo and diastolic dysfunction in vitro, increased cardiomyocyte apoptosis, and 
prominent cardiac fibrosis111. Presumably, as a consequence of systolic dysfunction of the left 
ventricle, the Zyxko mice failed to upregulate systolic blood pressure to the same extent as age-
matched wild type control animals111. A compromised renal function, as alternative explanation, 
could be excluded due to an unaltered renal excretion of cystatin C111.  
It has previously been reported that aldosterone in combination with high salt intake upregulates 
cardiac renin-angiotensin system components to induce a pro-inflammatory as well as pro-fibrotic 
response in the heart. In this cardiac remodeling situation, the pro-apoptotic signaling intermediate 
ASK1 (apoptosis signal-regulating kinase-1) serves as a molecular cross-bridge between 
mineralocorticoid and angiotensin II signaling140–143. Nonetheless, the DOCA-salt hypertension model 
in mice quickly progresses to severe hypertension and requires ingestion of a large amount of NaCl 
making it a less reliable model for studying the consequences of hypertension in humans like cardiac 
fibrosis144,145. In the present work, we wanted to elucidate the molecular mechanism underlying the 
development of cardiac fibrosis in Zyxko mice upon angiotensin II-mediated hypertension which is 
much more pronounced in this model than in the DOCA-salt model. In our previous study employing 
the DOCA-salt model, the degree of cardiac fibrosis in the 12 months old Zyxko mice may have 
already been at or beyond the maximum, so that subtle differences or even the onset of fibrosis 
could not be analyzed properly111. Hence, investigation of much younger animals might provide 
better insight into development of the cardiac phenotype in these animals. As such, mice aged 3, 6 
and 12 months were explored for the extent of cardiac fibrosis in the angiotensin II-induced 
experimental hypertension model. 
At baseline, Zyxko and WT mice showed comparable systolic and diastolic blood pressure levels in all 
three age groups as well as a comparable systolic cardiac function. However, in Zyxko mice both left 
ventricular filling velocities in diastole were significantly reduced pointing to a possible impairment 
in diastolic cardiac function131–134. This phenotype at baseline, possible diastolic dysfunction with 
preserved systolic function, is reminiscent of the human condition of restrictive cardiomyopathy 
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(RCM). RCM is a disease of the myocardium which is characterized by restricted ventricular filling 
due to increased ventricular stiffness. RCM is not a frequent form of cardiac dysfunction; however, 
the prognosis is quite poor146. RCM in the Zyxko mice might be attributed to a pro-fibrotic 
myocardium already in young and unchallenged animals. 
After the 14-day angiotensin II exposure, changes in blood pressure were comparable in WT and 
Zyxko mice in all age groups, i.e. they were all clearly hypertensive. Cardiac systolic performance was 
comparable at 3 months, started to be deregulated at 6 months and was significantly impaired at 12 
months of age in Zyxko animals. Interestingly, angiotensin II treatment also significantly reduced 
both the passive (E) and active (A) left ventricular velocities in diastole both in wild type and Zyxko 
mice. In the literature, for the same  dose of angiotensin II and duration of exposure, only reductions 
in the A level have been reported147. This ambiguity might come from the different genetic 
backgrounds of the mice under investigation. To analyze cardiac diastolic function, the E/A ratio is 
the most frequently used indicator. However, after angiotensin II treatment, both wild type and 
Zyxko mice showed similar E/A ratios between 1 and 2, indicative of a normal diastolic performance. 
Of note, however, is that the magnitude of reduction of these velocities in angiotensin II-treated 
Zyxko mice was much less as compared to the wild type control mice. Less reduction in these two 
velocities in the Zyxko mice might be ascribed to an impairment in left ventricular relaxation in 
diastole caused by a much stiffer ventricle131,134. This assumption is corroborated by the finding in 
working hearts isolated from DOCA-salt treated 12 months old Zyxko mice that relaxation of the left 
ventricle in these is about two times slower than in working hearts isolated from age-matched 
DOCA-salt treated wild type animals111. However, to fully prove that diastolic cardiac function in 
hypertensive Zyxko mice is due to a much stiffer left ventricle further high-resolution ultrasound 
imaging analyses are necessary.  
Somewhat unexpectedly, angiotensin II treatment induced significant cardiac hypertrophy only in 
wild type mice in all age groups. It was previously shown that angiotensin II type-1 receptor–
associated protein (ATRAP) can promote internalization of the AT1 (angiotensin II type-1) receptor 
and thus prevent development of angiotensin II–induced cardiac hypertrophy, fibrosis, and 
inflammation148,149. However, the rather similar blood pressure elevation in Zyxko and wild type mice 
essentially eliminates the possibility of a reduced AT1 receptor abundance, e.g. in Zyxko 
cardiomyocytes. Another possibility could be that Zyxko mice attained the decompensation stage of 
hypertension-induced cardiac remodeling where the increased loss of cardiomyocyte is 
compensated by excess cardiac fibrosis14–16. This was in fact documented by the quite prominent 
deposition of fibrillar collagen in the left ventricular myocardium of hypertensive Zyxko mice 
irrespective of their age. Nonetheless, the overall degree of fibrosis and expression of pro-fibrotic 
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gene products further increased with age in these animals. This age-dependent pronouncement of 
cardiac fibrosis might potentiate the development of cardiac dysfunction in older mice.  
In pathological settings, alteration of ECM proteins such as collagen in terms of abundance, 
distribution and degree of crosslinking contributes to the development of both systolic and diastolic 
heart failure134. It has been previously reported that ventricular stiffness positively correlates with 
the degree of collagen crosslinking in the human failing heart150–152. In this context, in Zyxko mouse 
myocardium there was a quite prominent expression of lysyl oxidase (LOX), one of the major 
collagen crosslinking enzymes, which further increased with age. LOX is encoded as a pre-proLOX 
which then undergoes a series of post-translational modifications and finally in the extracellular 
milieu the active enzyme get secreated153. However, catalytically active forms of LOX have also been 
identified in the cytosolic and nuclear compartments of fibrogenic cells with unspecified 
substrates154. Analogous to extracellular LOX, nuclear LOX also is immunoreactive and sensitive to 
β-aminopropionitrile (BAPN, broad spectrum LOX inhibitor)154. Therefore, in the present study, 
detection of LOX in the nucleus and cytosol of myocardial cells conforms to the conventional 
thinking about this enzyme’s localization which is associated with its functions.  
Distinct LOX expression patterns have been reported to be associated with certain pathological 
conditions including fibrosis in the heart, lung, liver and kidney in both humans and murine models, 
tumor progression and metastasis38,155–158. In a recent study, it was found that in a mechanically 
stressed mouse heart LOX can control TGF--dependent transformation of fibroblasts to 
myofibroblasts37. Herein, we also observed that cardiac fibroblasts isolated from adult Zyxko mice (3 
months old) display significantly higher LOX expression together with that of CTGF and collagen 
1and 3 following TGF-1 treatment. More strikingly, even in the absence of TGF-1, Zyxko 
cardiac fibroblasts revealed a rather high expression of these pro-fibrotic gene products which 
matched the levels attained in wild type cardiac fibroblasts following TGF-1 treatment. Higher 
expression of pro-fibrotic genes under basal condition indicates that the cardiac fibroblasts isolated 
from Zyxko mice are already committed to transformation into myofibroblasts, and that this process 
is accentuated in the presence of TGF-1. A regulatory function of zyxin in epithelial to mesenchymal 
transition has been reported previously in lung cancer cells. It was found that TGF-1-dependent 
expression of zyxin was needed to maintain the balance of integrin α5/β1  thus preventing transition 
from the epithelial to mesenchymal phenotype159. Moreover, in the DOCA-salt model, the left 
ventricular myocardium of the hypertensive Zyxko mice exhibited an upregulation of TGF-1 
receptor, integrin α5/β1 and the phosphorylated form of focal adhesion kinase (FAK)111. During 
hypertension, mechanical deformation or stretch is directly sensed by integrins and further 
transduced through signaling molecules attached to the cortical actin cytoskeleton like focal 
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adhesion kinase (FAK)160,161. In fact, the genetic deletion of β-integrin or FAK in mice leads to 
spontaneous or stress-induced cardiac dysfunction162–164. 
TGF-1, a locally generated pro-fibrotic cytokine, has been implicated as a major stimulator for the 
phenotypic modulation of fibroblasts to myofibroblasts. Increased myocardial TGF-1 expression 
during cardiac hypertrophy and fibrosis has been shown for humans and experimental animals165. 
Treatment with angiotensin II has been reported to cause upregulation of TGF-1 in the myocardium 
to facilitate transformation of cardiac fibroblasts into myofibroblasts20. Along these lines, both 
animal models and clinical studies indicate that the ameliorative effects of ACE inhibitors and AT1 
receptor blockers are most likely mediated through antagonism of TGF-1 and its downstream 
effects in cardiac cells166. Our present findings of an increased pro-fibrotic gene expression in Zyxko 
cardiac fibroblasts and massive cardiac fibrosis following angiotensin II treatment suggest that zyxin 
prevents the transformation of cardiac fibroblasts to myofibroblasts. Therefore, in the absence of 
zyxin, transdifferentiation of cardiac fibroblasts might have been initiated already to get exaggerated 
in response to angiotensin II to spur cardiac fibrosis and subsequent cardiac dysfunction (Figure 5.3). 
 
Figure 5.3 Proposed model for the protective role of zyxin in hypertension-induced cardiac fibrosis 
Angiotensin II (Ang II) and transformation growth factor -1 (TGF-1) can act synergistically to transdiffentiate 
fibroblasts into myofibroblasts. The newly synthesized collagens by the myofibroblasts can then be further 
crosslinked to form insoluble collagen fiber deposits. Zyxin may prevent the transdifferentiation as well as the 
further lysyl oxidase (LOX)-dependent crosslinking of the soluble collagens.  
Age-dependent cardiac dysfunction in Zyxko mice might be the consequence of a stiffer left ventricle 
as a result of this overt collagen deposition. In this context, possible compensatory functions 
between zyxin and LPP might still be valid, but it is not clear whether this holds true for cardiac 
myocytes or fibroblasts. Although LPP is denoted as a differentiated smooth muscle cell specific 
protein and suggested not to be expressed in the heart96, Hooper et al. reported LPP to be present in 
the myocardium167,168 . Moreover, it was reported also that LPP expression is higher in cardiac 
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fibroblasts in comparison to cardiomyocyte, and was upregulated under conditions of  pressure 
overload (transaortic constriction model)168. Analyses of older Lppko as well as Lpp/Zyx double-
knockout mice will offer a further in-depth understanding of the possible interrelation  between LPP 
and zyxin in cardiac remodeling and the possible target cell for this interaction. In a nutshell, the 
findings until now suggest the following sequence of events: zyxin-deficient myocardial endothelial 
cells release increased amounts of CTGF and TGF-157 that prime susceptible zyxin-deficient cardiac 
fibroblasts to transdifferentiate into myofibroblasts releasing large amounts of collagens and LOX, 
resulting in a much stiffened ECM which changes the already altered integrin-ECM interaction of the 
zyxin-null cardiomyocytes so that they undergo increased apoptosis rather than hypertrophy. 
Further studies will show whether this hypothesis is correct. If so, the mechanotransducer zyxin 
plays an important role in preventing cardiac remodeling in response to arterial hypertension on 
several levels and therefore represents an interesting drug target to prevent cardiomyopathies and 
ultimately heart failure. 
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6 Concluding remarks 
In this study, we have observed a protective role for two members of the zyxin family of LIM- 
domain containing proteins, zyxin and LPP, in the development of hypertension induced 
cardiovascular remodeling in a redundant fashion. Although both zyxin and LPP are ubiquitously 
expressed during embryonic development as well as in adults, a differential tissue distribution 
of zyxin and LPP was reported. The level of zyxin is five times higher than that of LPP in 
fibroblasts91, whereas LPP is highly expressed in smooth muscle tissues96. Still controversial, LPP 
has been reported to be absent in the heart91. In experimental hypertension models, mice 
lacking functional zyxin displayed a vascular phenotype in very old animals (18 months old) but 
a cardiac phenotype in animals as young as 3 months of age. On the other hand, young Lppko 
mice (3 months old) reveal some changes as compared to age-matched wild type or zyxin 
knockout mice that may point to the development of a vascular phenotype.  
The differential temporal appearance of these two hypertension-induced phenotypes can be 
correlated with the degree of zyxin and LPP abundance inside the cells regulating the 
pathogenesis. To develop a vascular phenotype, VSMCs are the main contributor, hence, LPP 
may have a stronger potential to suppress the vascular phenotype developing in Zyxko mice 
until the very old age. Conversely, the higher abundance of LPP and subsequent lack of a 
complete functional compensation by zyxin in VSMCs may result in the earlier onset of the 
vascular phenotype in Lppko mice. Cardiac fibroblasts might be the principal regulators of 
hypertension-dependent cardiac fibrosis. Therefore, Zyxko mice may be more prone to unveil a 
cardiac phenotype at much younger age due to an insufficient compensation by LPP in this 
organ. Nevertheless, analysis of much older Lppko and Lpp/Zyx double-knockout mice is 
necessary to answer the ever emerging questions regarding their functional compensation, at 
least, in the context of hypertension induced cardiac remodeling. 
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